{"ticker": {"uuid": "657ea37c-cb05-4201-9479-c74266bacc37", "symbol": "ATYR", "name": "aTyr Pharma, Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "charts": {"tiers": [{"count": 29, "label": "Direct company coverage"}, {"count": 0, "label": "Industry context"}, {"count": 0, "label": "Sector context"}], "events": [{"count": 18, "label": "Earnings"}, {"count": 4, "label": "Regulatory and legal"}, {"count": 3, "label": "Market update"}, {"count": 2, "label": "Analyst action"}, {"count": 1, "label": "Balance sheet"}, {"count": 1, "label": "Deals and strategy"}], "sources": [{"label": "The National Law Review", "count": 4}, {"label": "TradingView", "count": 4}, {"label": "simplywall.st", "count": 2}, {"label": "vinanet.vn", "count": 2}, {"label": "Moomoo", "count": 2}, {"label": "MarketBeat", "count": 2}, {"label": "Freedom Broker", "count": 1}, {"label": "BioXconomy", "count": 1}]}, "insights": [{"text": "Early balanced news score", "tone": "neutral", "label": "Weighted tone", "value": "49/100"}, {"text": "6.64 effective stories after overlap and weighting.", "tone": "neutral", "label": "Evidence confidence", "value": "23/100"}, {"text": "Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.", "tone": "neutral", "label": "Market reaction", "value": "Early company-news score"}, {"text": "82/100 evidence concentration around this catalyst.", "tone": "neutral", "label": "Primary event", "value": "Earnings"}, {"text": "99% of weighted evidence is company-specific.", "tone": "positive", "label": "Company focus", "value": "29"}, {"text": "lower dispersion means the independent stories agree more closely.", "tone": "neutral", "label": "Evidence agreement", "value": "23/100"}, {"text": "+7.7% over one week, +11.2% over four weeks, trend inactive, and below fair value.", "tone": "negative", "label": "Trend context", "value": "Trend inactive"}, {"text": "aTyr Pharma And 2 Other Penny Stocks With Promising Potential", "tone": "neutral", "label": "Latest direct headline", "value": "Neutral"}], "classifier": {"events": [{"count": 18, "event": "earnings", "label": "Earnings", "weight": 11.42}, {"count": 4, "event": "regulatory", "label": "Regulatory and legal", "weight": 2.4}, {"count": 3, "event": "general", "label": "Market update", "weight": 1.8}, {"count": 2, "event": "analyst", "label": "Analyst action", "weight": 1.2}, {"count": 1, "event": "liquidity", "label": "Balance sheet", "weight": 0.6}, {"count": 1, "event": "deals", "label": "Deals and strategy", "weight": 0.6}], "pipeline": {"status": "healthy", "providers_attempted": 4, "providers_with_results": 4, "raw_articles": 89, "unique_stories": 51, "duplicates_removed": 38, "relevant_stories": 29, "matched_archive_stories": 43, "current_evidence": 16, "direct_evidence": 29, "archive_articles": 7, "durable_story_count": 30, "durable_evidence_used": true, "durable_collected_at": "2026-08-31T04:31:14.281004+00:00"}, "confidence": 82, "primary_event": "earnings", "primary_label": "Earnings", "negative_events": 10, "positive_events": 6}, "updated_at": "2026-08-31T07:24:45.447143+00:00", "total_unique": 30, "total_fetched": 30, "interpretation": {"tone": "neutral", "label": "Early company-news score", "risks": [], "badges": ["Provisional evidence"], "summary": "Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.", "confidence": 23, "event_label": "Earnings", "opportunities": [], "classification": "provisional", "sentiment_word": "balanced"}, "market_context": {"trend_tone": "negative", "latest_week": "2026-08-28", "trend_label": "Trend inactive", "latest_close": 0.54, "trend_signal": "0", "one_week_move": 7.7, "reaction_tone": "positive", "fair_value_gap": -74.3, "four_week_move": 11.2, "reaction_label": "Price confirming higher", "fair_value_tone": "positive", "market_dynamics": 0.58516, "market_sentence": "+7.7% over one week, +11.2% over four weeks, trend inactive, and below fair value.", "fair_value_label": "Below fair value", "twelve_week_move": 14.9, "relative_strength": -49.786453, "has_market_context": true, "expectation_direction": "undecided", "expectation_probability": 47.3615, "market_dynamics_buy_signal": false}, "total_relevant": 29, "pipeline_health": {"status": "healthy", "providers_attempted": 4, "providers_with_results": 4, "raw_articles": 89, "unique_stories": 51, "duplicates_removed": 38, "relevant_stories": 29, "matched_archive_stories": 43, "current_evidence": 16, "direct_evidence": 29, "archive_articles": 7, "durable_story_count": 29, "durable_evidence_used": true, "durable_collected_at": "2026-08-31T07:24:45.447143+00:00"}, "sentiment_summary": {"tone": "neutral", "label": "Early balanced news score", "score": 49, "total": 30, "neutral": 13, "negative": 10, "positive": 6, "raw_score": 45, "confidence": 23, "dispersion": 23, "story_count": 29, "window_days": 30, "direct_share": 99, "source_count": 10, "score_version": "evidence-v10", "evidence_count": 16, "evidence_status": "provisional", "information_mass": 0.287, "weighting_method": "event-aware exponential freshness decay", "newest_article_at": "2026-08-26T17:24:07+00:00", "direct_story_count": 29, "effective_articles": 6.64, "sector_story_count": 0, "direct_source_count": 10, "industry_story_count": 0, "source_concentration": 0.3365, "directional_story_count": 16}, "articles": [{"url": "https://news.google.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?oc=5", "tier": "direct", "title": "aTyr Pharma And 2 Other Penny Stocks With Promising Potential", "topics": [], "summary": "", "age_days": 4.6, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-08-26T17:24:07+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 20.4, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.01092, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "26 Aug 2026 17:24", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMiigJBVV95cUxORFh5ajRXZ0E3NXlQc0M1bEZESVp5VzVxVFdPNHRUYWFOeVdvYWh6ak1hWGxJb1JNNHVyVmVqQ3NqN0tPaF9KelQ3Z3JPckJJUmxPTWVRRkZORWhUZ19xaUpIemdyeXFUNm5DM0YxdU5jZUEzTTNaMTBfcUFaX2dOckFmWVpFOWs0cDVtVFllMDJVR1V1TDNOT1F2QmtTUFRwT2RLRmFsRW5pZjZsVkctU05CMWgwWDVCd3Nnd1hMMkY1TVc2a2FVOHV0ZG5VRlFSRnZTSHhMR0R4TWZPbzFyTVZCbzd5LXNjQ181TTNFLVpCbi16QnI2UjlIc2s5RmIxUFhOaWJKZl9jQQ?oc=5", "tier": "direct", "title": "aTyr (ATYR) Financial Results: Profit Per Share Surpasses Its Benchmark in the Latest Reading; The Stock Ends Down 0.20% in the Latest Session - EBITDA Margin Trends", "topics": [], "summary": "", "age_days": 7.1, "is_stale": false, "sentiment": "positive", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiigJBVV95cUxORFh5ajRXZ0E3NXlQc0M1bEZESVp5VzVxVFdPNHRUYWFOeVdvYWh6ak1hWGxJb1JNNHVyVmVqQ3NqN0tPaF9KelQ3Z3JPckJJUmxPTWVRRkZORWhUZ19xaUpIemdyeXFUNm5DM0YxdU5jZUEzTTNaMTBfcUFaX2dOckFmWVpFOWs0cDVtVFllMDJVR1V1TDNOT1F2QmtTUFRwT2RLRmFsRW5pZjZsVkctU05CMWgwWDVCd3Nnd1hMMkY1TVc2a2FVOHV0ZG5VRlFSRnZTSHhMR0R4TWZPbzFyTVZCbzd5LXNjQ181TTNFLVpCbi16QnI2UjlIc2s5RmIxUFhOaWJKZl9jQQ?oc=5", "source_name": "vinanet.vn", "published_at": "2026-08-24T05:33:38+00:00", "tone_signals": ["Beat expectations"], "company_focus": 1.0, "freshness_pct": 37.5, "sentiment_pct": 75, "evidence_basis": "headline_only", "evidence_share": 28.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.080134, "influence_label": "High", "event_confidence": 61, "company_focus_pct": 100, "evidence_strength": 61, "published_display": "24 Aug 2026 05:33", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "28"}, {"url": "https://fbroker.kz/en/news/51511-fb-atyr-pharma-shares-have-over-500-upside-as-the-company-prepares-a-new-phase-iii-en-2", "tier": "direct", "title": "FB: aTyr Pharma shares have over 500% upside as the company prepares a new Phase III", "topics": ["Life Sciences"], "summary": "Freedom Broker analysts have maintained a \"Buy\" rating on aTyr Pharma (ATYR) shares with a $3.50 price target, suggesting a 536% upside from the current price. The key catalyst is the FDA's expected comments by the end of August on the protocol for a new Phase III study of efzofitimod for pulmonary sarcoidosis. Despite the potential, analysts note the investment remains high-risk, requiring a new Phase III trial and additional funding.", "age_days": 13.7, "is_stale": false, "sentiment": "positive", "event_type": "analyst", "tier_label": "Direct company coverage", "event_label": "Analyst action", "source_kind": "publisher", "source_link": "https://fbroker.kz/en/news/51511-fb-atyr-pharma-shares-have-over-500-upside-as-the-company-prepares-a-new-phase-iii-en-2", "source_name": "Freedom Broker", "published_at": "2026-08-17T15:41:11", "tone_signals": ["Positive financial language"], "company_focus": 1.0, "freshness_pct": 4.3, "sentiment_pct": 59, "evidence_basis": "archived_article", "evidence_share": 1.7, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.00497, "influence_label": "Low", "event_confidence": 61, "company_focus_pct": 100, "evidence_strength": 32, "published_display": "17 Aug 2026 15:41", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "1.7"}, {"url": "https://news.google.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?oc=5", "tier": "direct", "title": "Here's Why We're A Bit Worried About aTyr Pharma's (NASDAQ:ATYR) Cash Burn Situation", "topics": [], "summary": "", "age_days": 17.0, "is_stale": false, "sentiment": "neutral", "event_type": "liquidity", "tier_label": "Direct company coverage", "event_label": "Balance sheet", "source_kind": "publisher", "source_link": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-08-14T07:00:00+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 18.5, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.017544, "influence_label": "None", "event_confidence": 77, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "14 Aug 2026 07:00", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOZTJ6Zng5aXppdmZiZDBCOUN1OTdNZDB5MkhyaExCM2RpXzJyMm1XNWk1UHVFYTVRQ1VhN0stOTdjUGo2UWxaLU9odjdIUzBLOVN6cm9kTWxRb2FqVlZwWlpvRVlpUU9iLXBlOUp3bVdBa0phVm9Zb0VsWkMxOFZpaEY5RlM5Z3drNkdJd19hcDJIelIwTnlXejFlTDRxbnhLUDduTg?oc=5", "tier": "direct", "title": "ATYR Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares - Free Cash Flow Trends", "topics": [], "summary": "", "age_days": 17.0, "is_stale": false, "sentiment": "negative", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOZTJ6Zng5aXppdmZiZDBCOUN1OTdNZDB5MkhyaExCM2RpXzJyMm1XNWk1UHVFYTVRQ1VhN0stOTdjUGo2UWxaLU9odjdIUzBLOVN6cm9kTWxRb2FqVlZwWlpvRVlpUU9iLXBlOUp3bVdBa0phVm9Zb0VsWkMxOFZpaEY5RlM5Z3drNkdJd19hcDJIelIwTnlXejFlTDRxbnhLUDduTg?oc=5", "source_name": "vinanet.vn", "published_at": "2026-08-14T07:00:00+00:00", "tone_signals": ["Negative financial language"], "company_focus": 1.0, "freshness_pct": 9.5, "sentiment_pct": 43, "evidence_basis": "headline_only", "evidence_share": 3.8, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.010781, "influence_label": "Low", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 33, "published_display": "14 Aug 2026 07:00", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "3.8"}, {"url": "https://www.moomoo.com/news/post/74490072/wells-fargo-maintains-atyr-pharma-atyrus-with-hold-rating-maintains", "tier": "direct", "title": "Wells Fargo Maintains ATyr Pharma(ATYR.US) With Hold Rating, Maintains Target Price $1", "topics": ["Financial Markets", "Life Sciences"], "summary": "Wells Fargo has reaffirmed its Hold rating for ATyr Pharma (ATYR.US) and maintained its price target at $1. This indicates that Wells Fargo believes the stock will perform in line with the market.", "age_days": 18.6, "is_stale": false, "sentiment": "neutral", "event_type": "analyst", "tier_label": "Direct company coverage", "event_label": "Analyst action", "source_kind": "publisher", "source_link": "https://www.moomoo.com/news/post/74490072/wells-fargo-maintains-atyr-pharma-atyrus-with-hold-rating-maintains", "source_name": "Moomoo", "published_at": "2026-08-12T16:14:07", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 1.4, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.000889, "influence_label": "None", "event_confidence": 61, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "12 Aug 2026 16:14", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPazdpZ2tWVThuRHhzYnQzLWdRS3pFSEh3WXpCRmppUjU1NDBzV0x0NGZKc1RfSlJLRV83OG12WVJoenNZQ2F6c0lmOW41MkMzaWNPUkZ3MGRIb28xeVdFVHRjaFZXYjJrR1Z0alhfeUJRZnFjcmdTbnB0Z3JsQnVuN29BNHQzNXNoM0QxRmUwRUFKamlMb2U2TGZGLXJyTzl6cWdveXRET3dPX3VuWmpCQkVwbHQ?oc=5", "tier": "direct", "title": "Q3 Earnings Forecast for aTyr Pharma Issued By HC Wainwright", "topics": [], "summary": "", "age_days": 18.9, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPazdpZ2tWVThuRHhzYnQzLWdRS3pFSEh3WXpCRmppUjU1NDBzV0x0NGZKc1RfSlJLRV83OG12WVJoenNZQ2F6c0lmOW41MkMzaWNPUkZ3MGRIb28xeVdFVHRjaFZXYjJrR1Z0alhfeUJRZnFjcmdTbnB0Z3JsQnVuN29BNHQzNXNoM0QxRmUwRUFKamlMb2U2TGZGLXJyTzl6cWdveXRET3dPX3VuWmpCQkVwbHQ?oc=5", "source_name": "MarketBeat", "published_at": "2026-08-12T10:40:21+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 7.3, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.006019, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "12 Aug 2026 10:40", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.bioxconomy.com/legal/atyr-biogen-city-therapeutics-name-legal-chiefs", "tier": "direct", "title": "aTyr, Biogen, City name legal chiefs", "topics": ["Finance", "Life Sciences"], "summary": "Several biopharma companies, including aTyr Pharma, Biogen, City Therapeutics, CytomX Therapeutics, and Sanofi, have recently appointed new chief legal officers or general counsels. These appointments reflect a focus on bolstering legal and compliance functions as these companies advance their therapeutic programs and expand their operations. The new legal chiefs bring extensive experience in the biopharmaceutical and biotechnology industries to their respective roles.", "age_days": 19.5, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.bioxconomy.com/legal/atyr-biogen-city-therapeutics-name-legal-chiefs", "source_name": "BioXconomy", "published_at": "2026-08-11T20:14:28", "tone_signals": ["Business expansion"], "company_focus": 0.78, "freshness_pct": 0.1, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 6.3e-05, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 78, "evidence_strength": 0, "published_display": "11 Aug 2026 20:14", "direction_included": false, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://m.investing.com/news/stock-market-news/why-is-atyr-pharma-stock-gaining-today-93CH-4849078?ampMode=1", "tier": "direct", "title": "Why is aTyr Pharma stock gaining today?", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "aTyr Pharma's stock rose 1.8% in pre-open trading after announcing better-than-expected second-quarter results and a significant operational restructuring. The company reported a narrower loss per share, a 60% workforce reduction, and a focused pipeline on its lead candidate, efzofitimod, for interstitial lung disease. Investors are reacting positively to the extended cash runway, upcoming FDA feedback on a Phase 3 protocol, and completed enrollment in a Phase 2 study.", "age_days": 20.8, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://m.investing.com/news/stock-market-news/why-is-atyr-pharma-stock-gaining-today-93CH-4849078?ampMode=1", "source_name": "Investing.com", "published_at": "2026-08-10T13:12:25", "tone_signals": ["Negative financial language"], "company_focus": 1.0, "freshness_pct": 5.6, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.008304, "influence_label": "None", "event_confidence": 61, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "10 Aug 2026 13:12", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.nasdaq.com/articles/atyr-pharma-q2-net-loss-narrows-cuts-workforce-60-advance-efzofitimod-phase-3", "tier": "direct", "title": "ATyr Pharma Q2 Net Loss Narrows; Cuts Workforce By 60% To Advance Efzofitimod Into Phase 3", "topics": ["BIOTECH", "Biotech", "CLINICAL-TRIALS", "Clinical Trials", "EARNINGS", "Earnings"], "summary": "(RTTNews) - aTyr Pharma, Inc. (ATYR) announced second-quarter 2026 results and prioritised a corporate restructuring involving a 60% workforce reduction to advance its lead therapeutic candidate, Efzofitimod, in interstitial lung disease (ILD). aTyr's lead therapeutic candidate, efzofitimod, is a biologic immunomodulator in clinical development for the treatment of ILD, including pulmonary sarcoidosis and systemic sclerosis (SSc)-related ILD (SSc-ILD), that can cause inflammation and progressive fibrosis, or scarring, of the lungs. Second Quarter Results For the second quarter of 2026, net los", "age_days": 21.0, "is_stale": false, "sentiment": "positive", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.nasdaq.com/articles/atyr-pharma-q2-net-loss-narrows-cuts-workforce-60-advance-efzofitimod-phase-3", "source_name": "nasdaq.com", "published_at": "2026-08-10T07:45:47+00:00", "tone_signals": ["Loss narrowed"], "company_focus": 0.78, "freshness_pct": 5.5, "sentiment_pct": 66, "evidence_basis": "archived_article", "evidence_share": 2.9, "score_included": true, "duplicate_count": 3, "evidence_weight": 0.008396, "influence_label": "Medium", "event_confidence": 61, "company_focus_pct": 78, "evidence_strength": 39, "published_display": "10 Aug 2026 07:45", "direction_included": true, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "2.9"}, {"url": "https://www.fiercebiotech.com/biotech/atyr-lays-60-workforce-fund-2nd-attempt-phase-3-success-lung-disease-drug", "tier": "direct", "title": "aTyr lays off 60% of workforce to fund 2nd attempt at phase 3 success for lung disease drug", "topics": ["Earnings", "Life Sciences"], "summary": "aTyr Pharma is laying off 60% of its workforce to conserve resources for a second attempt at phase 3 success for its lung disease drug, efzofitimod. The company is awaiting FDA feedback on a new phase 3 study protocol after the drug missed its primary endpoint in a previous trial. The restructuring is expected to save $13 million annually and extend the cash runway into late 2028, though additional capital will still be needed.", "age_days": 21.1, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.fiercebiotech.com/biotech/atyr-lays-60-workforce-fund-2nd-attempt-phase-3-success-lung-disease-drug", "source_name": "Fierce Biotech", "published_at": "2026-08-10T06:12:25", "tone_signals": ["Negative financial language"], "company_focus": 1.0, "freshness_pct": 5.4, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.005835, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "10 Aug 2026 06:12", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.natlawreview.com/press-releases/securities-lawsuit-alert-atyr-pharma-inc-atyr-investors-contact-levi", "tier": "direct", "title": "Securities Lawsuit Alert: aTyr Pharma, Inc. (ATYR) Investors - Contact Levi & Korsinsky Before December 8, 2025", "topics": ["Finance", "Life Sciences"], "summary": "Levi & Korsinsky LLP has issued a securities lawsuit alert for investors of aTyr Pharma, Inc. (NASDAQ:ATYR). The alert concerns a class action lawsuit filed against aTyr Pharma, Inc. seeking to recover losses for shareholders who were adversely affected by alleged securities fraud between November 7, 2024, and September 12, 2025. The lawsuit alleges that the company made misleading statements regarding the efficacy of its drug Efzofitimod, particularly its ability to allow patients to taper steroid usage, prior to a negative study announcement that caused a significant stock price drop.", "age_days": 21.1, "is_stale": false, "sentiment": "negative", "event_type": "regulatory", "tier_label": "Direct company coverage", "event_label": "Regulatory and legal", "source_kind": "publisher", "source_link": "https://www.natlawreview.com/press-releases/securities-lawsuit-alert-atyr-pharma-inc-atyr-investors-contact-levi", "source_name": "The National Law Review", "published_at": "2026-08-10T06:12:25", "tone_signals": ["Legal or regulatory risk", "Negative market reaction"], "company_focus": 1.0, "freshness_pct": 12.4, "sentiment_pct": 23, "evidence_basis": "archived_article", "evidence_share": 17.8, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.051041, "influence_label": "High", "event_confidence": 77, "company_focus_pct": 100, "evidence_strength": 59, "published_display": "10 Aug 2026 06:12", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "17.8"}, {"url": "https://www.moomoo.com/news/flash/22980958/atyr-pharma-announces-second-quarter-2026-results-program-prioritization-and", "tier": "direct", "title": "ATyr Pharma Announces Second Quarter 2026 Res", "topics": ["Earnings", "Life Sciences"], "summary": "This article announces ATyr Pharma's second quarter 2026 results. The content is currently a placeholder and does not contain detailed financial information or a full report.", "age_days": 22.8, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.moomoo.com/news/flash/22980958/atyr-pharma-announces-second-quarter-2026-results-program-prioritization-and", "source_name": "Moomoo", "published_at": "2026-08-08T11:40:47", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 4.2, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 5, "evidence_weight": 0.004057, "influence_label": "None", "event_confidence": 69, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "08 Aug 2026 11:40", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.tradingview.com/news/tradingview:fa02aaf192025:0-atyr-pharma-inc-2q-2026-net-loss-10-3m-eps-0-11-10-q-summary", "tier": "direct", "title": "aTYR PHARMA INC 2Q 2026: Net loss $(10.3M), EPS $(0.11) \u2014 10-Q Summary", "topics": ["Earnings", "Life Sciences"], "summary": "aTyr Pharma (ATYR) reported a reduced net loss of $(10.3M) and an EPS of $(0.11) for Q2 2026, primarily due to lower research-and-development spending. The company plans to initiate a new global Phase 3 study for pulmonary sarcoidosis despite its EFZO-FIT trial missing its primary endpoint, and has implemented an operational restructuring including a 60% workforce reduction to conserve cash. aTyr Pharma is also advancing its preclinical candidate ATYR0101 and expanding its tRNA synthetase discovery platform.", "age_days": 23.2, "is_stale": false, "sentiment": "negative", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.tradingview.com/news/tradingview:fa02aaf192025:0-atyr-pharma-inc-2q-2026-net-loss-10-3m-eps-0-11-10-q-summary", "source_name": "TradingView", "published_at": "2026-08-08T02:40:31", "tone_signals": ["Deteriorating financial comparison"], "company_focus": 1.0, "freshness_pct": 4.0, "sentiment_pct": 40, "evidence_basis": "archived_article", "evidence_share": 2.7, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.007802, "influence_label": "Medium", "event_confidence": 61, "company_focus_pct": 100, "evidence_strength": 36, "published_display": "08 Aug 2026 02:40", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "2.7"}, {"url": "https://www.tradingview.com/news/tradingview:a22c4b37b362b:0-atyr-pharma-posts-q2-2026-net-loss-of-10-3m-58-9m-cash-prioritizes-efzofitimod-in-ild", "tier": "direct", "title": "aTYR Pharma posts Q2 2026 net loss of $10.3M, $58.9M cash; prioritizes efzofitimod in ILD", "topics": ["Earnings", "Finance", "Life Sciences"], "summary": "aTYR Pharma reported a Q2 2026 net loss of $10.3 million and ended the quarter with $58.9 million in cash. The company is implementing a corporate restructuring, including a 60% workforce reduction, to conserve capital and focus on its lead candidate efzofitimod for interstitial lung disease (ILD). They have completed enrollment for a Phase 2 study in SSc-ILD and are awaiting FDA feedback on a Phase 3 protocol for pulmonary sarcoidosis.", "age_days": 23.3, "is_stale": false, "sentiment": "negative", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.tradingview.com/news/tradingview:a22c4b37b362b:0-atyr-pharma-posts-q2-2026-net-loss-of-10-3m-58-9m-cash-prioritizes-efzofitimod-in-ild", "source_name": "TradingView", "published_at": "2026-08-07T23:40:47", "tone_signals": ["Negative financial language"], "company_focus": 1.0, "freshness_pct": 3.9, "sentiment_pct": 41, "evidence_basis": "archived_article", "evidence_share": 2.0, "score_included": true, "duplicate_count": 2, "evidence_weight": 0.005746, "influence_label": "Low", "event_confidence": 61, "company_focus_pct": 100, "evidence_strength": 34, "published_display": "07 Aug 2026 23:40", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "2"}, {"url": "https://www.gurufocus.com/news/9018269/atyr-looks-136-overvalued-on-gf-value-as-it-restructures-amid-pulmonary-sarcoidosis-focus", "tier": "direct", "title": "ATYR Looks 13.6% Overvalued on GF Value\u2122 as It Restructures Amid Pulmonary Sarcoidosis Focus", "topics": ["Earnings", "Finance", "Financial Markets", "Life Sciences"], "summary": "aTyr Pharma Inc (NASDAQ: ATYR) announced its Q2 financial results and a major strategic restructuring, including a 60% workforce reduction, to prioritize its efzofitimod program for interstitial lung diseases. Despite an extremely high Price-to-Sales ratio of 255.7x and ongoing unprofitability, the company is preparing for FDA feedback on its Phase 3 pulmonary sarcoidosis study protocol. The stock is considered modestly overvalued by GuruFocus's GF Value\u2122 and has a low GF Score\u2122 of 18/100, though insider buying and stable guru ownership provide some positive signals.", "age_days": 23.3, "is_stale": false, "sentiment": "negative", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.gurufocus.com/news/9018269/atyr-looks-136-overvalued-on-gf-value-as-it-restructures-amid-pulmonary-sarcoidosis-focus", "source_name": "GuruFocus", "published_at": "2026-08-07T23:39:14", "tone_signals": ["Negative valuation view"], "company_focus": 1.0, "freshness_pct": 3.9, "sentiment_pct": 40, "evidence_basis": "archived_article", "evidence_share": 2.6, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.007537, "influence_label": "Medium", "event_confidence": 61, "company_focus_pct": 100, "evidence_strength": 36, "published_display": "07 Aug 2026 23:39", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "2.6"}, {"url": "https://finance.yahoo.com/healthcare/articles/atyr-pharma-fiscal-q2-loss-203953251.html", "tier": "direct", "title": "Update: ATyr Pharma Fiscal Q2 Loss Narrows; Announces Restructuring Plans", "topics": ["Earnings", "Life Sciences"], "summary": "ATyr Pharma reported a narrower fiscal Q2 loss. The company also announced restructuring plans, with further details provided in the last three paragraphs of the article. Access to the full MT Newswires article requires a premium subscription.", "age_days": 23.4, "is_stale": false, "sentiment": "positive", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/healthcare/articles/atyr-pharma-fiscal-q2-loss-203953251.html", "source_name": "MT Newswires", "published_at": "2026-08-07T20:39:53+00:00", "tone_signals": ["Loss narrowed"], "company_focus": 1.0, "freshness_pct": 3.9, "sentiment_pct": 66, "evidence_basis": "archived_article", "evidence_share": 2.7, "score_included": true, "duplicate_count": 2, "evidence_weight": 0.007729, "influence_label": "Medium", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 42, "published_display": "07 Aug 2026 20:39", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "2.7"}, {"url": "https://finance.yahoo.com/markets/stocks/articles/atyr-pharma-q2-earnings-snapshot-202105965.html", "tier": "direct", "title": "Atyr Pharma: Q2 Earnings Snapshot", "topics": [], "summary": "", "age_days": 23.5, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "editorial_wire", "source_link": "https://finance.yahoo.com/markets/stocks/articles/atyr-pharma-q2-earnings-snapshot-202105965.html", "source_name": "Associated Press", "published_at": "2026-08-07T20:21:05+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 3.9, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.005304, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "07 Aug 2026 20:21", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQT01RMGQ4azhNOUc0alpGUXlnNGxQNmlOLVE0T1VmeXNka1pQNmE1NjBETkE1Vi0xcFRfdHJiTHh5eV9QYWpyX3JveTU4djlENGxDc2pqU0xfTEI2TW5XUlFhY1NUdjljaXJFU1UyWEtvRHlRZWgwdEkyX2dwWDM3VkdraHRhb3d4OVh5R2JxTkdVV3A2TzlNMlRlZWRTd1cxNHZqelRfZ2gwa00?oc=5", "tier": "direct", "title": "aTyr Pharma Q2 Results: EPS of $(0.11) beats estimates", "topics": [], "summary": "", "age_days": 24.0, "is_stale": false, "sentiment": "positive", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQT01RMGQ4azhNOUc0alpGUXlnNGxQNmlOLVE0T1VmeXNka1pQNmE1NjBETkE1Vi0xcFRfdHJiTHh5eV9QYWpyX3JveTU4djlENGxDc2pqU0xfTEI2TW5XUlFhY1NUdjljaXJFU1UyWEtvRHlRZWgwdEkyX2dwWDM3VkdraHRhb3d4OVh5R2JxTkdVV3A2TzlNMlRlZWRTd1cxNHZqelRfZ2gwa00?oc=5", "source_name": "scanx.trade", "published_at": "2026-08-07T07:00:00+00:00", "tone_signals": ["Beat expectations"], "company_focus": 1.0, "freshness_pct": 3.6, "sentiment_pct": 75, "evidence_basis": "headline_only", "evidence_share": 2.7, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.007655, "influence_label": "Medium", "event_confidence": 61, "company_focus_pct": 100, "evidence_strength": 51, "published_display": "07 Aug 2026 07:00", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "2.7"}, {"url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTFBldVdxV3ViZHRiZUFCMXEwVFlYUzQ1azc3TVVxT1lBSDlhVUY0ZTlLazVmOFJGRnV0SEMydWp3LU11bWRxQThaV3NCVjE5d29HbTVvX1NOMlp1eExESHZrMWxoNlJvUQ?oc=5", "tier": "direct", "title": "aTyr Pharma (ATYR) Earnings Date and Reports 2026", "topics": [], "summary": "", "age_days": 24.0, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiZkFVX3lxTFBldVdxV3ViZHRiZUFCMXEwVFlYUzQ1azc3TVVxT1lBSDlhVUY0ZTlLazVmOFJGRnV0SEMydWp3LU11bWRxQThaV3NCVjE5d29HbTVvX1NOMlp1eExESHZrMWxoNlJvUQ?oc=5", "source_name": "MarketBeat", "published_at": "2026-08-07T07:00:00+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 3.6, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.002946, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "07 Aug 2026 07:00", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://natlawreview.com/press-releases/class-action-lawsuit-filed-atyr-pharma-inc-atyr-join-december-8-2025-1", "tier": "direct", "title": "Class Action Lawsuit Filed: aTyr Pharma, Inc. (ATYR) \u2013 Join by December 8, 2025 - Contact Levi & Korsinsky", "topics": ["Finance", "Financial Markets", "Life Sciences"], "summary": "A class action securities lawsuit has been filed against aTyr Pharma, Inc. (ATYR) on behalf of shareholders who suffered losses between November 7, 2024, and September 12, 2025. The lawsuit alleges that the company made false and misleading statements regarding the efficacy of its drug Efzofitimod, particularly its ability to allow patients to taper steroid usage. The stock price dropped significantly after aTyr announced that the EFZO-FIT study did not meet its primary endpoint, leading to an 83.2% decline in one day.", "age_days": 24.1, "is_stale": false, "sentiment": "negative", "event_type": "regulatory", "tier_label": "Direct company coverage", "event_label": "Regulatory and legal", "source_kind": "publisher", "source_link": "https://natlawreview.com/press-releases/class-action-lawsuit-filed-atyr-pharma-inc-atyr-join-december-8-2025-1", "source_name": "The National Law Review", "published_at": "2026-08-07T04:11:24", "tone_signals": ["Legal or regulatory risk", "Negative market reaction"], "company_focus": 1.0, "freshness_pct": 9.2, "sentiment_pct": 20, "evidence_basis": "archived_article", "evidence_share": 14.2, "score_included": true, "duplicate_count": 3, "evidence_weight": 0.040619, "influence_label": "High", "event_confidence": 77, "company_focus_pct": 100, "evidence_strength": 62, "published_display": "07 Aug 2026 04:11", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "14.2"}, {"url": "https://www.stocktitan.net/sec-filings/ATYR/schedule-13g-a-a-tyr-pharma-inc-amended-passive-investment-disclosure-79ac14d52f56.html", "tier": "direct", "title": "FMR LLC and Abigail Johnson (ATYR) disclose 2.5% ATYR Pharma ownership", "topics": ["Finance", "Life Sciences"], "summary": "FMR LLC and Abigail P. Johnson have reported a 2.5% passive ownership stake in ATYR Pharma Inc. This disclosure, made via an amended Schedule 13G, indicates that FMR LLC beneficially owns 2,471,418 shares, with sole voting power over 2,464,141 shares and sole dispositive power over all 2,471,418 shares. Abigail P. Johnson also holds sole dispositive power over the same number of shares, reflecting her control over FMR-related entities.", "age_days": 24.7, "is_stale": false, "sentiment": "neutral", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "publisher", "source_link": "https://www.stocktitan.net/sec-filings/ATYR/schedule-13g-a-a-tyr-pharma-inc-amended-passive-investment-disclosure-79ac14d52f56.html", "source_name": "Stock Titan", "published_at": "2026-08-06T14:10:32", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 8.6, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.006405, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "06 Aug 2026 14:10", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.natlawreview.com/press-releases/shareholders-atyr-pharma-inc-atyr-protect-your-rights-december-8-2025", "tier": "direct", "title": "Shareholders of aTyr Pharma, Inc. (ATYR): Protect Your Rights Before December 8, 2025 - Contact Levi & Korsinsky", "topics": ["Finance", "Life Sciences"], "summary": "Levi & Korsinsky LLP has filed a class action securities lawsuit against aTyr Pharma, Inc. (ATYR) on behalf of shareholders who suffered losses between November 7, 2024, and September 12, 2025. The lawsuit alleges that aTyr Pharma made false and misleading statements regarding the efficacy of its drug Efzofitimod. The stock price dropped significantly after the company announced that a key study did not meet its primary endpoint, causing an 83.2% decline in one day.", "age_days": 25.8, "is_stale": false, "sentiment": "negative", "event_type": "regulatory", "tier_label": "Direct company coverage", "event_label": "Regulatory and legal", "source_kind": "publisher", "source_link": "https://www.natlawreview.com/press-releases/shareholders-atyr-pharma-inc-atyr-protect-your-rights-december-8-2025", "source_name": "The National Law Review", "published_at": "2026-08-05T11:43:30", "tone_signals": ["Legal or regulatory risk", "Negative market reaction"], "company_focus": 1.0, "freshness_pct": 7.8, "sentiment_pct": 34, "evidence_basis": "archived_article", "evidence_share": 7.7, "score_included": true, "duplicate_count": 2, "evidence_weight": 0.021965, "influence_label": "Medium", "event_confidence": 77, "company_focus_pct": 100, "evidence_strength": 44, "published_display": "05 Aug 2026 11:43", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "7.7"}, {"url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFAxR3hsQlUzVDdJRUd4Z2doN1NRTVlmU0Zjc2V5bVctZV96SUJ5NjBvcVhvZnhSYnVSRzBMenh6eEJESk9QbDFRS2NSUV9tWG1MTTljUDNlekVjZw?oc=5", "tier": "direct", "title": "LIFE|aTyr Pharma Ord Shs|Price:22.810|Chg%:+2.390", "topics": [], "summary": "", "age_days": 26.9, "is_stale": false, "sentiment": "positive", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFAxR3hsQlUzVDdJRUd4Z2doN1NRTVlmU0Zjc2V5bVctZV96SUJ5NjBvcVhvZnhSYnVSRzBMenh6eEJESk9QbDFRS2NSUV9tWG1MTTljUDNlekVjZw?oc=5", "source_name": "TradingKey", "published_at": "2026-08-04T09:45:31+00:00", "tone_signals": ["Positive market reaction"], "company_focus": 1.0, "freshness_pct": 0.0, "sentiment_pct": 60, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 9e-06, "influence_label": "Low", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 33, "published_display": "04 Aug 2026 09:45", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "<0.1"}, {"url": "https://natlawreview.com/press-releases/class-action-filed-against-atyr-pharma-inc-atyr-over-securities-violations", "tier": "direct", "title": "Class Action Filed Against aTyr Pharma, Inc. (ATYR) Over Securities Violations \u2013 Contact Levi & Korsinsky Today", "topics": ["Finance", "Financial Markets", "Life Sciences"], "summary": "A class action lawsuit has been filed against aTyr Pharma, Inc. (ATYR) alleging securities fraud between November 7, 2024, and September 12, 2025. The lawsuit claims the company made misleading statements regarding the efficacy of its drug Efzofitimod, particularly its ability to reduce steroid usage. This news follows a significant 83.2% stock price drop on September 15, 2025, after aTyr announced its EFZO-FIT study did not meet its primary endpoint.", "age_days": 27.2, "is_stale": false, "sentiment": "negative", "event_type": "regulatory", "tier_label": "Direct company coverage", "event_label": "Regulatory and legal", "source_kind": "publisher", "source_link": "https://natlawreview.com/press-releases/class-action-filed-against-atyr-pharma-inc-atyr-over-securities-violations", "source_name": "The National Law Review", "published_at": "2026-08-04T02:09:27", "tone_signals": ["Legal or regulatory risk", "Negative market reaction"], "company_focus": 1.0, "freshness_pct": 6.8, "sentiment_pct": 25, "evidence_basis": "archived_article", "evidence_share": 9.4, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.0268, "influence_label": "Medium", "event_confidence": 96, "company_focus_pct": 100, "evidence_strength": 55, "published_display": "04 Aug 2026 02:09", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "9.4"}, {"url": "https://www.marketscreener.com/news/alerts-on-ethos-technologies-q2-results-wrongly-attributed-to-atyr-pharma-withdrawn-ce7f50d9df89f720", "tier": "direct", "title": "Alerts on Ethos Technologies' Q2 results wrongly attributed to Atyr Pharma withdrawn", "topics": ["Earnings", "Life Sciences"], "summary": "MarketScreener has withdrawn alerts regarding Ethos Technologies' Q2 results that were erroneously attributed to aTyr Pharma, Inc. The original publication was made on August 3, 2026, at 04:48 pm EDT by Reuters. This correction highlights a data misattribution concerning financial reporting.", "age_days": 27.4, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.marketscreener.com/news/alerts-on-ethos-technologies-q2-results-wrongly-attributed-to-atyr-pharma-withdrawn-ce7f50d9df89f720", "source_name": "marketscreener.com", "published_at": "2026-08-03T21:09:27", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 2.2, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.002143, "influence_label": "None", "event_confidence": 61, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "03 Aug 2026 21:09", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.tradingview.com/news/reuters.com,2026:newsml_L8N440124:0-atyr-pharma-inc-expected-to-post-a-loss-of-12-cents-a-share-earnings-preview", "tier": "direct", "title": "aTyr Pharma Inc expected to post a loss of 12 cents a share - Earnings Preview", "topics": ["Earnings", "Life Sciences"], "summary": "aTyr Pharma Inc is projected to report a loss of 12 cents per share, according to an earnings preview. This information is sourced from Refinitiv and was published by Reuters. The full article is available on TradingView, which aggregates news from various sources.", "age_days": 27.8, "is_stale": false, "sentiment": "negative", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.tradingview.com/news/reuters.com,2026:newsml_L8N440124:0-atyr-pharma-inc-expected-to-post-a-loss-of-12-cents-a-share-earnings-preview", "source_name": "TradingView", "published_at": "2026-08-03T11:43:44", "tone_signals": ["Negative financial language"], "company_focus": 1.0, "freshness_pct": 2.1, "sentiment_pct": 41, "evidence_basis": "archived_article", "evidence_share": 1.1, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.00308, "influence_label": "Low", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 33, "published_display": "03 Aug 2026 11:43", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "1.1"}, {"url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOZk50ZURkdzNYZUNyQl8yWVBLOERFRG5YWlgxeTRGdE5fSVJSQzhmd25MU0drUnpYS3Y0OUxITlRMVU9WSFdsRFFiQV9fbHM0OTE4R3d0eHFiS3BWeGdRRmtzWnNoWG9wNS13OFVTQUIxN2VQMmJDVzUyRV9RaENFOW5IVk84NnBycVhEdmJDQ3JLcmRyVjZmaElONVhBQnFKdHJiYjhsdFI4YzBvTEE?oc=5", "tier": "direct", "title": "ATYR Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Shares Up 1.19% - Earnings Surprise Score", "topics": [], "summary": "", "age_days": 28.0, "is_stale": false, "sentiment": "negative", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOZk50ZURkdzNYZUNyQl8yWVBLOERFRG5YWlgxeTRGdE5fSVJSQzhmd25MU0drUnpYS3Y0OUxITlRMVU9WSFdsRFFiQV9fbHM0OTE4R3d0eHFiS3BWeGdRRmtzWnNoWG9wNS13OFVTQUIxN2VQMmJDVzUyRV9RaENFOW5IVk84NnBycVhEdmJDQ3JLcmRyVjZmaElONVhBQnFKdHJiYjhsdFI4YzBvTEE?oc=5", "source_name": "Vinanet", "published_at": "2026-08-03T07:00:00+00:00", "tone_signals": ["Negative financial language"], "company_focus": 1.0, "freshness_pct": 2.1, "sentiment_pct": 43, "evidence_basis": "headline_only", "evidence_share": 0.8, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.002346, "influence_label": "Low", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 31, "published_display": "03 Aug 2026 07:00", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0.8"}, {"url": "", "tier": "direct", "title": "aTyr Pharma, Inc. Revenue Breakdown \u2013 NASDAQ:ATYR", "topics": [], "summary": "", "age_days": 29.0, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.google.com/search?tbm=nws&q=%22aTyr+Pharma%2C+Inc.+Revenue+Breakdown+%E2%80%93+NASDAQ%3AATYR%22+%22TradingView%22", "source_name": "TradingView", "published_at": "2026-08-02T07:24:26.869763+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 1.8, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.001477, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "02 Aug 2026 07:24", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": true, "evidence_share_display": "0"}], "by_tier": {"direct": [{"url": "https://news.google.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?oc=5", "tier": "direct", "title": "aTyr Pharma And 2 Other Penny Stocks With Promising Potential", "topics": [], "summary": "", "age_days": 4.6, "is_stale": false, "provider": "google_news", "providers": ["archive", "google_news"], "sentiment": "neutral", "story_key": "ab09b22c4286c1aa90ffa852036ef4734a79de77527e49ecdd2024036420a8df", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-08-26T17:24:07+00:00", "source_names": ["simplywall.st"], "target_scope": "aTyr Pharma And 2 Other Penny Stocks With Promising Potential", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 20.4, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.01092, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["ATYR.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "26 Aug 2026 17:24", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "ATYR.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMiigJBVV95cUxORFh5ajRXZ0E3NXlQc0M1bEZESVp5VzVxVFdPNHRUYWFOeVdvYWh6ak1hWGxJb1JNNHVyVmVqQ3NqN0tPaF9KelQ3Z3JPckJJUmxPTWVRRkZORWhUZ19xaUpIemdyeXFUNm5DM0YxdU5jZUEzTTNaMTBfcUFaX2dOckFmWVpFOWs0cDVtVFllMDJVR1V1TDNOT1F2QmtTUFRwT2RLRmFsRW5pZjZsVkctU05CMWgwWDVCd3Nnd1hMMkY1TVc2a2FVOHV0ZG5VRlFSRnZTSHhMR0R4TWZPbzFyTVZCbzd5LXNjQ181TTNFLVpCbi16QnI2UjlIc2s5RmIxUFhOaWJKZl9jQQ?oc=5", "tier": "direct", "title": "aTyr (ATYR) Financial Results: Profit Per Share Surpasses Its Benchmark in the Latest Reading; The Stock Ends Down 0.20% in the Latest Session - EBITDA Margin Trends", "topics": [], "summary": "", "age_days": 7.1, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "positive", "story_key": "92832eaade7e2c1da90fd17de8414b3f3bf3ce45a00527661212eb3f7530651e", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiigJBVV95cUxORFh5ajRXZ0E3NXlQc0M1bEZESVp5VzVxVFdPNHRUYWFOeVdvYWh6ak1hWGxJb1JNNHVyVmVqQ3NqN0tPaF9KelQ3Z3JPckJJUmxPTWVRRkZORWhUZ19xaUpIemdyeXFUNm5DM0YxdU5jZUEzTTNaMTBfcUFaX2dOckFmWVpFOWs0cDVtVFllMDJVR1V1TDNOT1F2QmtTUFRwT2RLRmFsRW5pZjZsVkctU05CMWgwWDVCd3Nnd1hMMkY1TVc2a2FVOHV0ZG5VRlFSRnZTSHhMR0R4TWZPbzFyTVZCbzd5LXNjQ181TTNFLVpCbi16QnI2UjlIc2s5RmIxUFhOaWJKZl9jQQ?oc=5", "source_name": "vinanet.vn", "published_at": "2026-08-24T05:33:38+00:00", "source_names": ["vinanet.vn"], "target_scope": "aTyr (ATYR) Financial Results: Profit Per Share Surpasses Its Benchmark in the Latest Reading", "tone_signals": ["Beat expectations"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 37.5, "sentiment_pct": 75, "evidence_basis": "headline_only", "evidence_share": 28.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.080134, "influence_label": "High", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "google_news", "event_confidence": 61, "model_confidence": 0.59, "provider_symbols": ["ATYR.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 61, "published_display": "24 Aug 2026 05:33", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "28", "target_provider_symbol": "ATYR.ARCHIVE", "provider_directional_mass": null}, {"url": "https://fbroker.kz/en/news/51511-fb-atyr-pharma-shares-have-over-500-upside-as-the-company-prepares-a-new-phase-iii-en-2", "tier": "direct", "title": "FB: aTyr Pharma shares have over 500% upside as the company prepares a new Phase III", "topics": ["Life Sciences"], "summary": "Freedom Broker analysts have maintained a \"Buy\" rating on aTyr Pharma (ATYR) shares with a $3.50 price target, suggesting a 536% upside from the current price. The key catalyst is the FDA's expected comments by the end of August on the protocol for a new Phase III study of efzofitimod for pulmonary sarcoidosis. Despite the potential, analysts note the investment remains high-risk, requiring a new Phase III trial and additional funding.", "age_days": 13.7, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage", "archive"], "sentiment": "positive", "story_key": "447ec40debe0e6808240d688549d440bfde443f689bd0d8d77e47ddad5f34248", "event_type": "analyst", "tier_label": "Direct company coverage", "event_label": "Analyst action", "source_kind": "publisher", "source_link": "https://fbroker.kz/en/news/51511-fb-atyr-pharma-shares-have-over-500-upside-as-the-company-prepares-a-new-phase-iii-en-2", "source_name": "Freedom Broker", "published_at": "2026-08-17T15:41:11", "source_names": ["Freedom Broker"], "target_scope": "FB: aTyr Pharma shares have over 500% upside as the company prepares a new Phase III Freedom Broker analysts have maintained a \"Buy\" rating on aTyr Pharma (ATYR) shares with a $3.50 price target, suggesting a 536% upside from the current price.", "tone_signals": ["Positive financial language"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 4.3, "sentiment_pct": 59, "evidence_basis": "archived_article", "evidence_share": 1.7, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.00497, "influence_label": "Low", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 61, "model_confidence": 0.481, "provider_symbols": ["ATYR", "ATYR.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 32, "published_display": "17 Aug 2026 15:41", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "1.7", "target_provider_symbol": "ATYR", "provider_directional_mass": 0.318}, {"url": "https://news.google.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?oc=5", "tier": "direct", "title": "Here's Why We're A Bit Worried About aTyr Pharma's (NASDAQ:ATYR) Cash Burn Situation", "topics": [], "summary": "", "age_days": 17.0, "is_stale": false, "provider": "google_news", "providers": ["google_news"], "sentiment": "neutral", "story_key": "d35f1981410efef3b4f79a86ac06d3e6a7b4afcddd6d6ce1af4bdca4f6b4d215", "event_type": "liquidity", "tier_label": "Direct company coverage", "event_label": "Balance sheet", "source_kind": "publisher", "source_link": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-08-14T07:00:00+00:00", "source_names": ["simplywall.st"], "target_scope": "Here's Why We're A Bit Worried About aTyr Pharma's (NASDAQ:ATYR) Cash Burn Situation", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 18.5, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.017544, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 77, "model_confidence": 0.4, "provider_symbols": ["ATYR.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "14 Aug 2026 07:00", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "ATYR.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOZTJ6Zng5aXppdmZiZDBCOUN1OTdNZDB5MkhyaExCM2RpXzJyMm1XNWk1UHVFYTVRQ1VhN0stOTdjUGo2UWxaLU9odjdIUzBLOVN6cm9kTWxRb2FqVlZwWlpvRVlpUU9iLXBlOUp3bVdBa0phVm9Zb0VsWkMxOFZpaEY5RlM5Z3drNkdJd19hcDJIelIwTnlXejFlTDRxbnhLUDduTg?oc=5", "tier": "direct", "title": "ATYR Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares - Free Cash Flow Trends", "topics": [], "summary": "", "age_days": 17.0, "is_stale": false, "provider": "google_news", "providers": ["archive", "google_news"], "sentiment": "negative", "story_key": "40eb4b5b6d9288054653227fa5b3834be9c3b3a4f94a2dbc0e8bd0f8b3373152", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOZTJ6Zng5aXppdmZiZDBCOUN1OTdNZDB5MkhyaExCM2RpXzJyMm1XNWk1UHVFYTVRQ1VhN0stOTdjUGo2UWxaLU9odjdIUzBLOVN6cm9kTWxRb2FqVlZwWlpvRVlpUU9iLXBlOUp3bVdBa0phVm9Zb0VsWkMxOFZpaEY5RlM5Z3drNkdJd19hcDJIelIwTnlXejFlTDRxbnhLUDduTg?oc=5", "source_name": "vinanet.vn", "published_at": "2026-08-14T07:00:00+00:00", "source_names": ["Vinanet", "vinanet.vn"], "target_scope": "ATYR Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares - Free Cash Flow Trends", "tone_signals": ["Negative financial language"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 9.5, "sentiment_pct": 43, "evidence_basis": "headline_only", "evidence_share": 3.8, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.010781, "influence_label": "Low", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.461, "provider_symbols": ["ATYR.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 33, "published_display": "14 Aug 2026 07:00", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "3.8", "target_provider_symbol": "ATYR.ARCHIVE", "provider_directional_mass": null}, {"url": "https://www.moomoo.com/news/post/74490072/wells-fargo-maintains-atyr-pharma-atyrus-with-hold-rating-maintains", "tier": "direct", "title": "Wells Fargo Maintains ATyr Pharma(ATYR.US) With Hold Rating, Maintains Target Price $1", "topics": ["Financial Markets", "Life Sciences"], "summary": "Wells Fargo has reaffirmed its Hold rating for ATyr Pharma (ATYR.US) and maintained its price target at $1. This indicates that Wells Fargo believes the stock will perform in line with the market.", "age_days": 18.6, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage", "archive"], "sentiment": "neutral", "story_key": "8c7ee5e47d0c9ffeef1b8a3bdbaad8a72672b1be5dbf2dea15201fea01f296e6", "event_type": "analyst", "tier_label": "Direct company coverage", "event_label": "Analyst action", "source_kind": "publisher", "source_link": "https://www.moomoo.com/news/post/74490072/wells-fargo-maintains-atyr-pharma-atyrus-with-hold-rating-maintains", "source_name": "Moomoo", "published_at": "2026-08-12T16:14:07", "source_names": ["Moomoo"], "target_scope": "Wells Fargo Maintains ATyr Pharma(ATYR.US) With Hold Rating, Maintains Target Price $1 Wells Fargo has reaffirmed its Hold rating for ATyr Pharma (ATYR.US) and maintained its price target at $1.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 1.4, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.000889, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 61, "model_confidence": 0.4, "provider_symbols": ["ATYR", "ATYR.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "12 Aug 2026 16:14", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "ATYR", "provider_directional_mass": 0.0201}, {"url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPazdpZ2tWVThuRHhzYnQzLWdRS3pFSEh3WXpCRmppUjU1NDBzV0x0NGZKc1RfSlJLRV83OG12WVJoenNZQ2F6c0lmOW41MkMzaWNPUkZ3MGRIb28xeVdFVHRjaFZXYjJrR1Z0alhfeUJRZnFjcmdTbnB0Z3JsQnVuN29BNHQzNXNoM0QxRmUwRUFKamlMb2U2TGZGLXJyTzl6cWdveXRET3dPX3VuWmpCQkVwbHQ?oc=5", "tier": "direct", "title": "Q3 Earnings Forecast for aTyr Pharma Issued By HC Wainwright", "topics": [], "summary": "", "age_days": 18.9, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "neutral", "story_key": "2c5b1330c27bf64fe59ec397c79cb40235c7a503f0a016b5469b08e51ba4b8dd", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPazdpZ2tWVThuRHhzYnQzLWdRS3pFSEh3WXpCRmppUjU1NDBzV0x0NGZKc1RfSlJLRV83OG12WVJoenNZQ2F6c0lmOW41MkMzaWNPUkZ3MGRIb28xeVdFVHRjaFZXYjJrR1Z0alhfeUJRZnFjcmdTbnB0Z3JsQnVuN29BNHQzNXNoM0QxRmUwRUFKamlMb2U2TGZGLXJyTzl6cWdveXRET3dPX3VuWmpCQkVwbHQ?oc=5", "source_name": "MarketBeat", "published_at": "2026-08-12T10:40:21+00:00", "source_names": ["MarketBeat"], "target_scope": "Q3 Earnings Forecast for aTyr Pharma Issued By HC Wainwright", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 7.3, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.006019, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "google_news", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": ["ATYR.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "12 Aug 2026 10:40", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "ATYR.ARCHIVE", "provider_directional_mass": null}, {"url": "https://www.bioxconomy.com/legal/atyr-biogen-city-therapeutics-name-legal-chiefs", "tier": "direct", "title": "aTyr, Biogen, City name legal chiefs", "topics": ["Finance", "Life Sciences"], "summary": "Several biopharma companies, including aTyr Pharma, Biogen, City Therapeutics, CytomX Therapeutics, and Sanofi, have recently appointed new chief legal officers or general counsels. These appointments reflect a focus on bolstering legal and compliance functions as these companies advance their therapeutic programs and expand their operations. The new legal chiefs bring extensive experience in the biopharmaceutical and biotechnology industries to their respective roles.", "age_days": 19.5, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage", "archive"], "sentiment": "neutral", "story_key": "cf9c02bdc4ce3f387f5fada13feb8128ef8036fb81813eaf41a88b14d32769fe", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.bioxconomy.com/legal/atyr-biogen-city-therapeutics-name-legal-chiefs", "source_name": "BioXconomy", "published_at": "2026-08-11T20:14:28", "source_names": ["BioXconomy"], "target_scope": "aTyr, Biogen, City name legal chiefs Several biopharma companies, including aTyr Pharma, Biogen, City Therapeutics, CytomX Therapeutics, and Sanofi, have recently appointed new chief legal officers or general counsels.", "tone_signals": ["Business expansion"], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.1, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 6.3e-05, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.527, "provider_symbols": ["ATYR", "ATYR.ARCHIVE", "BIIB"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 0, "published_display": "11 Aug 2026 20:14", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "ATYR", "provider_directional_mass": 0.048}, {"url": "https://m.investing.com/news/stock-market-news/why-is-atyr-pharma-stock-gaining-today-93CH-4849078?ampMode=1", "tier": "direct", "title": "Why is aTyr Pharma stock gaining today?", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "aTyr Pharma's stock rose 1.8% in pre-open trading after announcing better-than-expected second-quarter results and a significant operational restructuring. The company reported a narrower loss per share, a 60% workforce reduction, and a focused pipeline on its lead candidate, efzofitimod, for interstitial lung disease. Investors are reacting positively to the extended cash runway, upcoming FDA feedback on a Phase 3 protocol, and completed enrollment in a Phase 2 study.", "age_days": 20.8, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage", "archive"], "sentiment": "neutral", "story_key": "c6a98996e236e67fca8b535bf57f47da6751d8a8b1eebcd43767db94de4b0dd2", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://m.investing.com/news/stock-market-news/why-is-atyr-pharma-stock-gaining-today-93CH-4849078?ampMode=1", "source_name": "Investing.com", "published_at": "2026-08-10T13:12:25", "source_names": ["Investing.com"], "target_scope": "Why is aTyr Pharma stock gaining today? aTyr Pharma's stock rose 1.8% in pre-open trading after announcing better-than-expected second-quarter results and a significant operational restructuring.", "tone_signals": ["Negative financial language"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 5.6, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.008304, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 61, "model_confidence": 0.45, "provider_symbols": ["ATYR", "ATYR.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "10 Aug 2026 13:12", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "ATYR", "provider_directional_mass": 0.2959}, {"url": "https://www.nasdaq.com/articles/atyr-pharma-q2-net-loss-narrows-cuts-workforce-60-advance-efzofitimod-phase-3", "tier": "direct", "title": "ATyr Pharma Q2 Net Loss Narrows; Cuts Workforce By 60% To Advance Efzofitimod Into Phase 3", "topics": ["BIOTECH", "Biotech", "CLINICAL-TRIALS", "Clinical Trials", "EARNINGS", "Earnings"], "summary": "(RTTNews) - aTyr Pharma, Inc. (ATYR) announced second-quarter 2026 results and prioritised a corporate restructuring involving a 60% workforce reduction to advance its lead therapeutic candidate, Efzofitimod, in interstitial lung disease (ILD). aTyr's lead therapeutic candidate, efzofitimod, is a biologic immunomodulator in clinical development for the treatment of ILD, including pulmonary sarcoidosis and systemic sclerosis (SSc)-related ILD (SSc-ILD), that can cause inflammation and progressive fibrosis, or scarring, of the lungs. Second Quarter Results For the second quarter of 2026, net los", "age_days": 21.0, "is_stale": false, "provider": "eodhd", "providers": ["eodhd"], "sentiment": "positive", "story_key": "b85604cea77028692f33f5e8d6e7c90d6b1302d07f035624c9afc7e627a8bf9d", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.nasdaq.com/articles/atyr-pharma-q2-net-loss-narrows-cuts-workforce-60-advance-efzofitimod-phase-3", "source_name": "nasdaq.com", "published_at": "2026-08-10T07:45:47+00:00", "source_names": ["nasdaq.com"], "target_scope": "ATyr Pharma Q2 Net Loss Narrows (RTTNews) - aTyr Pharma, Inc. (ATYR) announced second-quarter 2026 results and prioritised a corporate restructuring involving a 60% workforce reduction to advance its lead therapeutic candidate, Efzofitimod, in interstitial lung disease (ILD). aTyr's lead therapeutic candidate, efzofitimod, is a biologic immunomodulator in clinical development for the treatment of ILD, including pulmonary sarcoidosis and systemic sclerosis (SSc)-related ILD (SSc-ILD), that can cause inflammation and progressive fibrosis, or scarring, of the lungs.", "tone_signals": ["Loss narrowed"], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 5.5, "sentiment_pct": 66, "evidence_basis": "archived_article", "evidence_share": 2.9, "score_included": true, "duplicate_count": 3, "durable_archive": false, "evidence_weight": 0.008396, "influence_label": "Medium", "provider_symbol": "ATYR.US", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 61, "model_confidence": 0.561, "provider_symbols": ["ATYR", "ATYR.ARCHIVE", "ATYR.US", "FDS"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 39, "published_display": "10 Aug 2026 07:45", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "2.9", "target_provider_symbol": "ATYR.US", "provider_directional_mass": 0.045}, {"url": "https://www.fiercebiotech.com/biotech/atyr-lays-60-workforce-fund-2nd-attempt-phase-3-success-lung-disease-drug", "tier": "direct", "title": "aTyr lays off 60% of workforce to fund 2nd attempt at phase 3 success for lung disease drug", "topics": ["Earnings", "Life Sciences"], "summary": "aTyr Pharma is laying off 60% of its workforce to conserve resources for a second attempt at phase 3 success for its lung disease drug, efzofitimod. The company is awaiting FDA feedback on a new phase 3 study protocol after the drug missed its primary endpoint in a previous trial. The restructuring is expected to save $13 million annually and extend the cash runway into late 2028, though additional capital will still be needed.", "age_days": 21.1, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage", "archive"], "sentiment": "neutral", "story_key": "540c4214948f745db6535fa9cbe96f3eed39e027bbba7611cba9fa270c08c75f", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.fiercebiotech.com/biotech/atyr-lays-60-workforce-fund-2nd-attempt-phase-3-success-lung-disease-drug", "source_name": "Fierce Biotech", "published_at": "2026-08-10T06:12:25", "source_names": ["Fierce Biotech"], "target_scope": "aTyr lays off 60% of workforce to fund 2nd attempt at phase 3 success for lung disease drug aTyr Pharma is laying off 60% of its workforce to conserve resources for a second attempt at phase 3 success for its lung disease drug, efzofitimod.", "tone_signals": ["Negative financial language"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 5.4, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.005835, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.45, "provider_symbols": ["ATYR", "ATYR.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "10 Aug 2026 06:12", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "ATYR", "provider_directional_mass": 0.3881}, {"url": "https://www.natlawreview.com/press-releases/securities-lawsuit-alert-atyr-pharma-inc-atyr-investors-contact-levi", "tier": "direct", "title": "Securities Lawsuit Alert: aTyr Pharma, Inc. (ATYR) Investors - Contact Levi & Korsinsky Before December 8, 2025", "topics": ["Finance", "Life Sciences"], "summary": "Levi & Korsinsky LLP has issued a securities lawsuit alert for investors of aTyr Pharma, Inc. (NASDAQ:ATYR). The alert concerns a class action lawsuit filed against aTyr Pharma, Inc. seeking to recover losses for shareholders who were adversely affected by alleged securities fraud between November 7, 2024, and September 12, 2025. The lawsuit alleges that the company made misleading statements regarding the efficacy of its drug Efzofitimod, particularly its ability to allow patients to taper steroid usage, prior to a negative study announcement that caused a significant stock price drop.", "age_days": 21.1, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage", "archive"], "sentiment": "negative", "story_key": "12ca47eea70ef5c68f2c0c134b2f1251c932b4d189bbe6292e2ca510eb0af71f", "event_type": "regulatory", "tier_label": "Direct company coverage", "event_label": "Regulatory and legal", "source_kind": "publisher", "source_link": "https://www.natlawreview.com/press-releases/securities-lawsuit-alert-atyr-pharma-inc-atyr-investors-contact-levi", "source_name": "The National Law Review", "published_at": "2026-08-10T06:12:25", "source_names": ["The National Law Review"], "target_scope": "Securities Lawsuit Alert: aTyr Pharma, Inc. (ATYR) Investors - Contact Levi & Korsinsky Before December 8, 2025 Levi & Korsinsky LLP has issued a securities lawsuit alert for investors of aTyr Pharma, Inc. (NASDAQ:ATYR). The alert concerns a class action lawsuit filed against aTyr Pharma, Inc.", "tone_signals": ["Legal or regulatory risk", "Negative market reaction"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 12.4, "sentiment_pct": 23, "evidence_basis": "archived_article", "evidence_share": 17.8, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.051041, "influence_label": "High", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 77, "model_confidence": 0.825, "provider_symbols": ["ATYR", "ATYR.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 59, "published_display": "10 Aug 2026 06:12", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "17.8", "target_provider_symbol": "ATYR", "provider_directional_mass": 0.7073}, {"url": "https://www.moomoo.com/news/flash/22980958/atyr-pharma-announces-second-quarter-2026-results-program-prioritization-and", "tier": "direct", "title": "ATyr Pharma Announces Second Quarter 2026 Res", "topics": ["Earnings", "Life Sciences"], "summary": "This article announces ATyr Pharma's second quarter 2026 results. The content is currently a placeholder and does not contain detailed financial information or a full report.", "age_days": 22.8, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage", "archive"], "sentiment": "neutral", "story_key": "2fddf73284f99647bd15594a1d99b4c60e771eef60fe48ffc7763c3e3cb73b5a", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.moomoo.com/news/flash/22980958/atyr-pharma-announces-second-quarter-2026-results-program-prioritization-and", "source_name": "Moomoo", "published_at": "2026-08-08T11:40:47", "source_names": ["Moomoo"], "target_scope": "ATyr Pharma Announces Second Quarter 2026 Res This article announces ATyr Pharma's second quarter 2026 results.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 4.2, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 5, "durable_archive": false, "evidence_weight": 0.004057, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 69, "model_confidence": 0.4, "provider_symbols": ["ATYR", "ATYR.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "08 Aug 2026 11:40", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "ATYR", "provider_directional_mass": 0.045}, {"url": "https://www.tradingview.com/news/tradingview:fa02aaf192025:0-atyr-pharma-inc-2q-2026-net-loss-10-3m-eps-0-11-10-q-summary", "tier": "direct", "title": "aTYR PHARMA INC 2Q 2026: Net loss $(10.3M), EPS $(0.11) \u2014 10-Q Summary", "topics": ["Earnings", "Life Sciences"], "summary": "aTyr Pharma (ATYR) reported a reduced net loss of $(10.3M) and an EPS of $(0.11) for Q2 2026, primarily due to lower research-and-development spending. The company plans to initiate a new global Phase 3 study for pulmonary sarcoidosis despite its EFZO-FIT trial missing its primary endpoint, and has implemented an operational restructuring including a 60% workforce reduction to conserve cash. aTyr Pharma is also advancing its preclinical candidate ATYR0101 and expanding its tRNA synthetase discovery platform.", "age_days": 23.2, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage", "archive"], "sentiment": "negative", "story_key": "8288eabcdda498e870616943782482930bcc5010d115cff8965e61b7b2fe3db8", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.tradingview.com/news/tradingview:fa02aaf192025:0-atyr-pharma-inc-2q-2026-net-loss-10-3m-eps-0-11-10-q-summary", "source_name": "TradingView", "published_at": "2026-08-08T02:40:31", "source_names": ["TradingView"], "target_scope": "aTYR PHARMA INC 2Q 2026: Net loss $(10.3M), EPS $(0.11) \u2014 10-Q Summary aTyr Pharma (ATYR) reported a reduced net loss of $(10.3M) and an EPS of $(0.11) for Q2 2026, primarily due to lower research-and-development spending. aTyr Pharma is also advancing its preclinical candidate ATYR0101 and expanding its tRNA synthetase discovery platform.", "tone_signals": ["Deteriorating financial comparison"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 4.0, "sentiment_pct": 40, "evidence_basis": "archived_article", "evidence_share": 2.7, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.007802, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 61, "model_confidence": 0.622, "provider_symbols": ["ATYR", "ATYR.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 36, "published_display": "08 Aug 2026 02:40", "direction_included": true, "sentiment_conflict": 0.336, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "2.7", "target_provider_symbol": "ATYR", "provider_directional_mass": 0.2298}, {"url": "https://www.tradingview.com/news/tradingview:a22c4b37b362b:0-atyr-pharma-posts-q2-2026-net-loss-of-10-3m-58-9m-cash-prioritizes-efzofitimod-in-ild", "tier": "direct", "title": "aTYR Pharma posts Q2 2026 net loss of $10.3M, $58.9M cash; prioritizes efzofitimod in ILD", "topics": ["Earnings", "Finance", "Life Sciences"], "summary": "aTYR Pharma reported a Q2 2026 net loss of $10.3 million and ended the quarter with $58.9 million in cash. The company is implementing a corporate restructuring, including a 60% workforce reduction, to conserve capital and focus on its lead candidate efzofitimod for interstitial lung disease (ILD). They have completed enrollment for a Phase 2 study in SSc-ILD and are awaiting FDA feedback on a Phase 3 protocol for pulmonary sarcoidosis.", "age_days": 23.3, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage", "archive"], "sentiment": "negative", "story_key": "e9734d85ef9ba6025e0b6fe3eddf256d470e656fecce9052140b3afd0e9ca18b", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.tradingview.com/news/tradingview:a22c4b37b362b:0-atyr-pharma-posts-q2-2026-net-loss-of-10-3m-58-9m-cash-prioritizes-efzofitimod-in-ild", "source_name": "TradingView", "published_at": "2026-08-07T23:40:47", "source_names": ["TradingView"], "target_scope": "aTYR Pharma posts Q2 2026 net loss of $10.3M, $58.9M cash aTYR Pharma reported a Q2 2026 net loss of $10.3 million and ended the quarter with $58.9 million in cash.", "tone_signals": ["Negative financial language"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 3.9, "sentiment_pct": 41, "evidence_basis": "archived_article", "evidence_share": 2.0, "score_included": true, "duplicate_count": 2, "durable_archive": false, "evidence_weight": 0.005746, "influence_label": "Low", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 61, "model_confidence": 0.481, "provider_symbols": ["ATYR", "ATYR.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 34, "published_display": "07 Aug 2026 23:40", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "2", "target_provider_symbol": "ATYR", "provider_directional_mass": 0.3314}, {"url": "https://www.gurufocus.com/news/9018269/atyr-looks-136-overvalued-on-gf-value-as-it-restructures-amid-pulmonary-sarcoidosis-focus", "tier": "direct", "title": "ATYR Looks 13.6% Overvalued on GF Value\u2122 as It Restructures Amid Pulmonary Sarcoidosis Focus", "topics": ["Earnings", "Finance", "Financial Markets", "Life Sciences"], "summary": "aTyr Pharma Inc (NASDAQ: ATYR) announced its Q2 financial results and a major strategic restructuring, including a 60% workforce reduction, to prioritize its efzofitimod program for interstitial lung diseases. Despite an extremely high Price-to-Sales ratio of 255.7x and ongoing unprofitability, the company is preparing for FDA feedback on its Phase 3 pulmonary sarcoidosis study protocol. The stock is considered modestly overvalued by GuruFocus's GF Value\u2122 and has a low GF Score\u2122 of 18/100, though insider buying and stable guru ownership provide some positive signals.", "age_days": 23.3, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage", "archive"], "sentiment": "negative", "story_key": "8632cdc76f746c2c37939795e492686c6656dff048927d1c2ecf6d3f7af4be78", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.gurufocus.com/news/9018269/atyr-looks-136-overvalued-on-gf-value-as-it-restructures-amid-pulmonary-sarcoidosis-focus", "source_name": "GuruFocus", "published_at": "2026-08-07T23:39:14", "source_names": ["GuruFocus"], "target_scope": "ATYR Looks 13.6% Overvalued on GF Value\u2122 as It Restructures Amid Pulmonary Sarcoidosis Focus aTyr Pharma Inc (NASDAQ: ATYR) announced its Q2 financial results and a major strategic restructuring, including a 60% workforce reduction, to prioritize its efzofitimod program for interstitial lung diseases.", "tone_signals": ["Negative valuation view"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 3.9, "sentiment_pct": 40, "evidence_basis": "archived_article", "evidence_share": 2.6, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.007537, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 61, "model_confidence": 0.619, "provider_symbols": ["ATYR", "ATYR.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 36, "published_display": "07 Aug 2026 23:39", "direction_included": true, "sentiment_conflict": 0.208, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "2.6", "target_provider_symbol": "ATYR", "provider_directional_mass": 0.2116}, {"url": "https://finance.yahoo.com/healthcare/articles/atyr-pharma-fiscal-q2-loss-203953251.html", "tier": "direct", "title": "Update: ATyr Pharma Fiscal Q2 Loss Narrows; Announces Restructuring Plans", "topics": ["Earnings", "Life Sciences"], "summary": "ATyr Pharma reported a narrower fiscal Q2 loss. The company also announced restructuring plans, with further details provided in the last three paragraphs of the article. Access to the full MT Newswires article requires a premium subscription.", "age_days": 23.4, "is_stale": false, "provider": "yfinance", "providers": ["archive", "yfinance"], "sentiment": "positive", "story_key": "a621b0d0bdd8d52d92ed6b2b105a7d582f153ee63f4e740d91538e4b52880251", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/healthcare/articles/atyr-pharma-fiscal-q2-loss-203953251.html", "source_name": "MT Newswires", "published_at": "2026-08-07T20:39:53+00:00", "source_names": ["MT Newswires"], "target_scope": "Update: ATyr Pharma Fiscal Q2 Loss Narrows ATyr Pharma reported a narrower fiscal Q2 loss.", "tone_signals": ["Loss narrowed"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 3.9, "sentiment_pct": 66, "evidence_basis": "archived_article", "evidence_share": 2.7, "score_included": true, "duplicate_count": 2, "durable_archive": false, "evidence_weight": 0.007729, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.557, "provider_symbols": ["ATYR", "ATYR.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 42, "published_display": "07 Aug 2026 20:39", "direction_included": true, "sentiment_conflict": 0.118, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "2.7", "target_provider_symbol": "ATYR", "provider_directional_mass": null}, {"url": "https://finance.yahoo.com/markets/stocks/articles/atyr-pharma-q2-earnings-snapshot-202105965.html", "tier": "direct", "title": "Atyr Pharma: Q2 Earnings Snapshot", "topics": [], "summary": "", "age_days": 23.5, "is_stale": false, "provider": "yfinance", "providers": ["archive", "yfinance"], "sentiment": "neutral", "story_key": "e2369ce6c8d546ed470129085e9f424ccf55e232efbaef50b97bbc243222f638", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "editorial_wire", "source_link": "https://finance.yahoo.com/markets/stocks/articles/atyr-pharma-q2-earnings-snapshot-202105965.html", "source_name": "Associated Press", "published_at": "2026-08-07T20:21:05+00:00", "source_names": ["Associated Press"], "target_scope": "Atyr Pharma: Q2 Earnings Snapshot", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 3.9, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.005304, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": ["ATYR", "ATYR.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "07 Aug 2026 20:21", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "ATYR", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQT01RMGQ4azhNOUc0alpGUXlnNGxQNmlOLVE0T1VmeXNka1pQNmE1NjBETkE1Vi0xcFRfdHJiTHh5eV9QYWpyX3JveTU4djlENGxDc2pqU0xfTEI2TW5XUlFhY1NUdjljaXJFU1UyWEtvRHlRZWgwdEkyX2dwWDM3VkdraHRhb3d4OVh5R2JxTkdVV3A2TzlNMlRlZWRTd1cxNHZqelRfZ2gwa00?oc=5", "tier": "direct", "title": "aTyr Pharma Q2 Results: EPS of $(0.11) beats estimates", "topics": [], "summary": "", "age_days": 24.0, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "positive", "story_key": "2d8bd350d9e8952f0038e064ab77a315aacc27ff8099c3951223a61f0a99e187", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQT01RMGQ4azhNOUc0alpGUXlnNGxQNmlOLVE0T1VmeXNka1pQNmE1NjBETkE1Vi0xcFRfdHJiTHh5eV9QYWpyX3JveTU4djlENGxDc2pqU0xfTEI2TW5XUlFhY1NUdjljaXJFU1UyWEtvRHlRZWgwdEkyX2dwWDM3VkdraHRhb3d4OVh5R2JxTkdVV3A2TzlNMlRlZWRTd1cxNHZqelRfZ2gwa00?oc=5", "source_name": "scanx.trade", "published_at": "2026-08-07T07:00:00+00:00", "source_names": ["scanx.trade"], "target_scope": "aTyr Pharma Q2 Results: EPS of $(0.11) beats estimates", "tone_signals": ["Beat expectations"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 3.6, "sentiment_pct": 75, "evidence_basis": "headline_only", "evidence_share": 2.7, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.007655, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "google_news", "event_confidence": 61, "model_confidence": 0.59, "provider_symbols": ["ATYR.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 51, "published_display": "07 Aug 2026 07:00", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "2.7", "target_provider_symbol": "ATYR.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTFBldVdxV3ViZHRiZUFCMXEwVFlYUzQ1azc3TVVxT1lBSDlhVUY0ZTlLazVmOFJGRnV0SEMydWp3LU11bWRxQThaV3NCVjE5d29HbTVvX1NOMlp1eExESHZrMWxoNlJvUQ?oc=5", "tier": "direct", "title": "aTyr Pharma (ATYR) Earnings Date and Reports 2026", "topics": [], "summary": "", "age_days": 24.0, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "neutral", "story_key": "7a712d58e18b5717faca6c5c1cf4a54eb8f3bddf04977ff899658ab301574ec6", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiZkFVX3lxTFBldVdxV3ViZHRiZUFCMXEwVFlYUzQ1azc3TVVxT1lBSDlhVUY0ZTlLazVmOFJGRnV0SEMydWp3LU11bWRxQThaV3NCVjE5d29HbTVvX1NOMlp1eExESHZrMWxoNlJvUQ?oc=5", "source_name": "MarketBeat", "published_at": "2026-08-07T07:00:00+00:00", "source_names": ["MarketBeat"], "target_scope": "aTyr Pharma (ATYR) Earnings Date and Reports 2026", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 3.6, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.002946, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "google_news", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": ["ATYR.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "07 Aug 2026 07:00", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "ATYR.ARCHIVE", "provider_directional_mass": null}, {"url": "https://natlawreview.com/press-releases/class-action-lawsuit-filed-atyr-pharma-inc-atyr-join-december-8-2025-1", "tier": "direct", "title": "Class Action Lawsuit Filed: aTyr Pharma, Inc. (ATYR) \u2013 Join by December 8, 2025 - Contact Levi & Korsinsky", "topics": ["Finance", "Financial Markets", "Life Sciences"], "summary": "A class action securities lawsuit has been filed against aTyr Pharma, Inc. (ATYR) on behalf of shareholders who suffered losses between November 7, 2024, and September 12, 2025. The lawsuit alleges that the company made false and misleading statements regarding the efficacy of its drug Efzofitimod, particularly its ability to allow patients to taper steroid usage. The stock price dropped significantly after aTyr announced that the EFZO-FIT study did not meet its primary endpoint, leading to an 83.2% decline in one day.", "age_days": 24.1, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage", "archive"], "sentiment": "negative", "story_key": "c4a0a850e38fa3703f89ccc1802c36f19b56c0a8255fc4d1c1dcc7162d4c6cc8", "event_type": "regulatory", "tier_label": "Direct company coverage", "event_label": "Regulatory and legal", "source_kind": "publisher", "source_link": "https://natlawreview.com/press-releases/class-action-lawsuit-filed-atyr-pharma-inc-atyr-join-december-8-2025-1", "source_name": "The National Law Review", "published_at": "2026-08-07T04:11:24", "source_names": ["The National Law Review"], "target_scope": "Class Action Lawsuit Filed: aTyr Pharma, Inc. (ATYR) \u2013 Join by December 8, 2025 - Contact Levi & Korsinsky A class action securities lawsuit has been filed against aTyr Pharma, Inc. (ATYR) on behalf of shareholders who suffered losses between November 7, 2024, and September 12, 2025. The stock price dropped significantly after aTyr announced that the EFZO-FIT study did not meet its primary endpoint, leading to an 83.2% decline in one day.", "tone_signals": ["Legal or regulatory risk", "Negative market reaction"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 9.2, "sentiment_pct": 20, "evidence_basis": "archived_article", "evidence_share": 14.2, "score_included": true, "duplicate_count": 3, "durable_archive": false, "evidence_weight": 0.040619, "influence_label": "High", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 77, "model_confidence": 0.84, "provider_symbols": ["ATYR", "ATYR.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 62, "published_display": "07 Aug 2026 04:11", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "14.2", "target_provider_symbol": "ATYR", "provider_directional_mass": 0.9301}, {"url": "https://www.stocktitan.net/sec-filings/ATYR/schedule-13g-a-a-tyr-pharma-inc-amended-passive-investment-disclosure-79ac14d52f56.html", "tier": "direct", "title": "FMR LLC and Abigail Johnson (ATYR) disclose 2.5% ATYR Pharma ownership", "topics": ["Finance", "Life Sciences"], "summary": "FMR LLC and Abigail P. Johnson have reported a 2.5% passive ownership stake in ATYR Pharma Inc. This disclosure, made via an amended Schedule 13G, indicates that FMR LLC beneficially owns 2,471,418 shares, with sole voting power over 2,464,141 shares and sole dispositive power over all 2,471,418 shares. Abigail P. Johnson also holds sole dispositive power over the same number of shares, reflecting her control over FMR-related entities.", "age_days": 24.7, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage", "archive"], "sentiment": "neutral", "story_key": "8026b3bb7fdb997ea845a719c429324bbd515b8dc83432bf5daad5ed86dda1cf", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "publisher", "source_link": "https://www.stocktitan.net/sec-filings/ATYR/schedule-13g-a-a-tyr-pharma-inc-amended-passive-investment-disclosure-79ac14d52f56.html", "source_name": "Stock Titan", "published_at": "2026-08-06T14:10:32", "source_names": ["Stock Titan"], "target_scope": "FMR LLC and Abigail Johnson (ATYR) disclose 2.5% ATYR Pharma ownership Johnson have reported a 2.5% passive ownership stake in ATYR Pharma Inc.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 8.6, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.006405, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": ["ATYR", "ATYR.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "06 Aug 2026 14:10", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "ATYR", "provider_directional_mass": 0.0378}, {"url": "https://www.natlawreview.com/press-releases/shareholders-atyr-pharma-inc-atyr-protect-your-rights-december-8-2025", "tier": "direct", "title": "Shareholders of aTyr Pharma, Inc. (ATYR): Protect Your Rights Before December 8, 2025 - Contact Levi & Korsinsky", "topics": ["Finance", "Life Sciences"], "summary": "Levi & Korsinsky LLP has filed a class action securities lawsuit against aTyr Pharma, Inc. (ATYR) on behalf of shareholders who suffered losses between November 7, 2024, and September 12, 2025. The lawsuit alleges that aTyr Pharma made false and misleading statements regarding the efficacy of its drug Efzofitimod. The stock price dropped significantly after the company announced that a key study did not meet its primary endpoint, causing an 83.2% decline in one day.", "age_days": 25.8, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage", "archive"], "sentiment": "negative", "story_key": "8bea641aca186319b286b9bc3b587f83e79092d570542689d1a2964627a554c1", "event_type": "regulatory", "tier_label": "Direct company coverage", "event_label": "Regulatory and legal", "source_kind": "publisher", "source_link": "https://www.natlawreview.com/press-releases/shareholders-atyr-pharma-inc-atyr-protect-your-rights-december-8-2025", "source_name": "The National Law Review", "published_at": "2026-08-05T11:43:30", "source_names": ["The National Law Review"], "target_scope": "Shareholders of aTyr Pharma, Inc. (ATYR): Protect Your Rights Before December 8, 2025 - Contact Levi & Korsinsky Levi & Korsinsky LLP has filed a class action securities lawsuit against aTyr Pharma, Inc. (ATYR) on behalf of shareholders who suffered losses between November 7, 2024, and September 12, 2025. The lawsuit alleges that aTyr Pharma made false and misleading statements regarding the efficacy of its drug Efzofitimod.", "tone_signals": ["Legal or regulatory risk", "Negative market reaction"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 7.8, "sentiment_pct": 34, "evidence_basis": "archived_article", "evidence_share": 7.7, "score_included": true, "duplicate_count": 2, "durable_archive": false, "evidence_weight": 0.021965, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 77, "model_confidence": 0.699, "provider_symbols": ["ATYR", "ATYR.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 44, "published_display": "05 Aug 2026 11:43", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "7.7", "target_provider_symbol": "ATYR", "provider_directional_mass": 0.7113}, {"url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFAxR3hsQlUzVDdJRUd4Z2doN1NRTVlmU0Zjc2V5bVctZV96SUJ5NjBvcVhvZnhSYnVSRzBMenh6eEJESk9QbDFRS2NSUV9tWG1MTTljUDNlekVjZw?oc=5", "tier": "direct", "title": "LIFE|aTyr Pharma Ord Shs|Price:22.810|Chg%:+2.390", "topics": [], "summary": "", "age_days": 26.9, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "positive", "story_key": "0a7b1e00f946b2d5922d53be896dc727fa395ca309bbc0c8bcbd1fedf8005962", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFAxR3hsQlUzVDdJRUd4Z2doN1NRTVlmU0Zjc2V5bVctZV96SUJ5NjBvcVhvZnhSYnVSRzBMenh6eEJESk9QbDFRS2NSUV9tWG1MTTljUDNlekVjZw?oc=5", "source_name": "TradingKey", "published_at": "2026-08-04T09:45:31+00:00", "source_names": ["TradingKey"], "target_scope": "LIFE|aTyr Pharma Ord Shs|Price:22.810|Chg%:+2.390", "tone_signals": ["Positive market reaction"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.0, "sentiment_pct": 60, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 9e-06, "influence_label": "Low", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "google_news", "event_confidence": 35, "model_confidence": 0.545, "provider_symbols": ["ATYR.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 33, "published_display": "04 Aug 2026 09:45", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "<0.1", "target_provider_symbol": "ATYR.ARCHIVE", "provider_directional_mass": null}, {"url": "https://natlawreview.com/press-releases/class-action-filed-against-atyr-pharma-inc-atyr-over-securities-violations", "tier": "direct", "title": "Class Action Filed Against aTyr Pharma, Inc. (ATYR) Over Securities Violations \u2013 Contact Levi & Korsinsky Today", "topics": ["Finance", "Financial Markets", "Life Sciences"], "summary": "A class action lawsuit has been filed against aTyr Pharma, Inc. (ATYR) alleging securities fraud between November 7, 2024, and September 12, 2025. The lawsuit claims the company made misleading statements regarding the efficacy of its drug Efzofitimod, particularly its ability to reduce steroid usage. This news follows a significant 83.2% stock price drop on September 15, 2025, after aTyr announced its EFZO-FIT study did not meet its primary endpoint.", "age_days": 27.2, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage", "archive"], "sentiment": "negative", "story_key": "45e94fb9ca43df1410abd265fdf5aedefe2a9b51a7d41846203d25b4cfda23fe", "event_type": "regulatory", "tier_label": "Direct company coverage", "event_label": "Regulatory and legal", "source_kind": "publisher", "source_link": "https://natlawreview.com/press-releases/class-action-filed-against-atyr-pharma-inc-atyr-over-securities-violations", "source_name": "The National Law Review", "published_at": "2026-08-04T02:09:27", "source_names": ["The National Law Review"], "target_scope": "Class Action Filed Against aTyr Pharma, Inc. (ATYR) Over Securities Violations \u2013 Contact Levi & Korsinsky Today A class action lawsuit has been filed against aTyr Pharma, Inc. (ATYR) alleging securities fraud between November 7, 2024, and September 12, 2025. This news follows a significant 83.2% stock price drop on September 15, 2025, after aTyr announced its EFZO-FIT study did not meet its primary endpoint.", "tone_signals": ["Legal or regulatory risk", "Negative market reaction"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 6.8, "sentiment_pct": 25, "evidence_basis": "archived_article", "evidence_share": 9.4, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.0268, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 96, "model_confidence": 0.815, "provider_symbols": ["ATYR", "ATYR.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 55, "published_display": "04 Aug 2026 02:09", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "9.4", "target_provider_symbol": "ATYR", "provider_directional_mass": 0.819}, {"url": "https://www.marketscreener.com/news/alerts-on-ethos-technologies-q2-results-wrongly-attributed-to-atyr-pharma-withdrawn-ce7f50d9df89f720", "tier": "direct", "title": "Alerts on Ethos Technologies' Q2 results wrongly attributed to Atyr Pharma withdrawn", "topics": ["Earnings", "Life Sciences"], "summary": "MarketScreener has withdrawn alerts regarding Ethos Technologies' Q2 results that were erroneously attributed to aTyr Pharma, Inc. The original publication was made on August 3, 2026, at 04:48 pm EDT by Reuters. This correction highlights a data misattribution concerning financial reporting.", "age_days": 27.4, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "14bd4896a66d45a9aaa974579a5472b6cfb68dc247c682e8fce99ddd1091a63d", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.marketscreener.com/news/alerts-on-ethos-technologies-q2-results-wrongly-attributed-to-atyr-pharma-withdrawn-ce7f50d9df89f720", "source_name": "marketscreener.com", "published_at": "2026-08-03T21:09:27", "source_names": ["marketscreener.com"], "target_scope": "Alerts on Ethos Technologies' Q2 results wrongly attributed to Atyr Pharma withdrawn MarketScreener has withdrawn alerts regarding Ethos Technologies' Q2 results that were erroneously attributed to aTyr Pharma, Inc.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 2.2, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.002143, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 61, "model_confidence": 0.4, "provider_symbols": ["ATYR", "ATYR.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "03 Aug 2026 21:09", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "ATYR", "provider_directional_mass": 0.019}, {"url": "https://www.tradingview.com/news/reuters.com,2026:newsml_L8N440124:0-atyr-pharma-inc-expected-to-post-a-loss-of-12-cents-a-share-earnings-preview", "tier": "direct", "title": "aTyr Pharma Inc expected to post a loss of 12 cents a share - Earnings Preview", "topics": ["Earnings", "Life Sciences"], "summary": "aTyr Pharma Inc is projected to report a loss of 12 cents per share, according to an earnings preview. This information is sourced from Refinitiv and was published by Reuters. The full article is available on TradingView, which aggregates news from various sources.", "age_days": 27.8, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage", "archive"], "sentiment": "negative", "story_key": "11541550d38e749ec5a616f900a9319f80021d7f9120aa23da9cda85c7686c9e", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.tradingview.com/news/reuters.com,2026:newsml_L8N440124:0-atyr-pharma-inc-expected-to-post-a-loss-of-12-cents-a-share-earnings-preview", "source_name": "TradingView", "published_at": "2026-08-03T11:43:44", "source_names": ["TradingView"], "target_scope": "aTyr Pharma Inc expected to post a loss of 12 cents a share - Earnings Preview aTyr Pharma Inc is projected to report a loss of 12 cents per share, according to an earnings preview.", "tone_signals": ["Negative financial language"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 2.1, "sentiment_pct": 41, "evidence_basis": "archived_article", "evidence_share": 1.1, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.00308, "influence_label": "Low", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.481, "provider_symbols": ["ATYR", "ATYR.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 33, "published_display": "03 Aug 2026 11:43", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "1.1", "target_provider_symbol": "ATYR", "provider_directional_mass": 0.3525}, {"url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOZk50ZURkdzNYZUNyQl8yWVBLOERFRG5YWlgxeTRGdE5fSVJSQzhmd25MU0drUnpYS3Y0OUxITlRMVU9WSFdsRFFiQV9fbHM0OTE4R3d0eHFiS3BWeGdRRmtzWnNoWG9wNS13OFVTQUIxN2VQMmJDVzUyRV9RaENFOW5IVk84NnBycVhEdmJDQ3JLcmRyVjZmaElONVhBQnFKdHJiYjhsdFI4YzBvTEE?oc=5", "tier": "direct", "title": "ATYR Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Shares Up 1.19% - Earnings Surprise Score", "topics": [], "summary": "", "age_days": 28.0, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "negative", "story_key": "7d4aaea2fa9e1b62be0c21a6fc494a8dc2beef63316046f70808f6fd8821c2c9", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOZk50ZURkdzNYZUNyQl8yWVBLOERFRG5YWlgxeTRGdE5fSVJSQzhmd25MU0drUnpYS3Y0OUxITlRMVU9WSFdsRFFiQV9fbHM0OTE4R3d0eHFiS3BWeGdRRmtzWnNoWG9wNS13OFVTQUIxN2VQMmJDVzUyRV9RaENFOW5IVk84NnBycVhEdmJDQ3JLcmRyVjZmaElONVhBQnFKdHJiYjhsdFI4YzBvTEE?oc=5", "source_name": "Vinanet", "published_at": "2026-08-03T07:00:00+00:00", "source_names": ["Vinanet"], "target_scope": "ATYR Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Shares Up 1.19% - Earnings Surprise Score", "tone_signals": ["Negative financial language"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 2.1, "sentiment_pct": 43, "evidence_basis": "headline_only", "evidence_share": 0.8, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.002346, "influence_label": "Low", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "google_news", "event_confidence": 53, "model_confidence": 0.461, "provider_symbols": ["ATYR.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 31, "published_display": "03 Aug 2026 07:00", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0.8", "target_provider_symbol": "ATYR.ARCHIVE", "provider_directional_mass": null}, {"url": "", "tier": "direct", "title": "aTyr Pharma, Inc. Revenue Breakdown \u2013 NASDAQ:ATYR", "topics": [], "summary": "", "age_days": 29.0, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "neutral", "story_key": "ad186e9c2a38c2f8fefcf7f161b614901f2cca61748263e3b37277b5cbc5a6e3", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.google.com/search?tbm=nws&q=%22aTyr+Pharma%2C+Inc.+Revenue+Breakdown+%E2%80%93+NASDAQ%3AATYR%22+%22TradingView%22", "source_name": "TradingView", "published_at": "2026-08-02T07:24:26.869763+00:00", "source_names": ["TradingView"], "target_scope": "aTyr Pharma, Inc. Revenue Breakdown \u2013 NASDAQ:ATYR", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 1.8, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.001477, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "snapshot", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": ["ATYR.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "02 Aug 2026 07:24", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": true, "evidence_share_display": "0", "target_provider_symbol": "ATYR.ARCHIVE", "provider_directional_mass": null}], "industry": [], "sector": []}, "detail_intelligence": {"headline": "Early balanced news score", "summary": "29 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.", "status": "provisional", "metrics": [{"label": "News score", "value": 49, "display": "49", "tone": "neutral", "note": "Early balanced news score"}, {"label": "Confidence", "value": 23, "display": "23", "tone": "negative", "note": "thin evidence"}, {"label": "Company news", "value": 99, "display": "99%", "tone": "positive", "note": "29 company stories"}, {"label": "Story agreement", "value": 77, "display": "77", "tone": "positive", "note": "23/100 difference"}], "confidence_drivers": [{"label": "Amount of evidence", "value": 6, "note": "0.287 after freshness weighting"}, {"label": "Source breadth", "value": 100, "note": "10 independent publishers"}, {"label": "Company relevance", "value": 99, "note": "share tied directly to this company"}, {"label": "Freshness", "value": 9, "note": "recency-weighted evidence"}, {"label": "Agreement", "value": 77, "note": "how closely stories agree"}, {"label": "Publisher mix", "value": 66, "note": "less reliance on one publisher"}], "freshness": 9, "source_independence": 66, "timeline": [{"date": "2026-08-02", "label": "02 Aug", "count": 1, "score": 50, "tone": "neutral", "x": 42.0, "y": 135.0, "volume_height": 7.4, "volume_y": 258.6}, {"date": "2026-08-03", "label": "03 Aug", "count": 3, "score": 44, "tone": "neutral", "x": 73.6, "y": 145.9, "volume_height": 22.3, "volume_y": 243.7}, {"date": "2026-08-04", "label": "04 Aug", "count": 2, "score": 25, "tone": "negative", "x": 105.2, "y": 180.5, "volume_height": 14.9, "volume_y": 251.1}, {"date": "2026-08-05", "label": "05 Aug", "count": 1, "score": 34, "tone": "negative", "x": 136.8, "y": 164.1, "volume_height": 7.4, "volume_y": 258.6}, {"date": "2026-08-06", "label": "06 Aug", "count": 1, "score": 50, "tone": "neutral", "x": 168.3, "y": 135.0, "volume_height": 7.4, "volume_y": 258.6}, {"date": "2026-08-07", "label": "07 Aug", "count": 7, "score": 37, "tone": "negative", "x": 199.9, "y": 158.7, "volume_height": 52.0, "volume_y": 214.0}, {"date": "2026-08-08", "label": "08 Aug", "count": 2, "score": 43, "tone": "neutral", "x": 231.5, "y": 147.7, "volume_height": 14.9, "volume_y": 251.1}, {"date": "2026-08-09", "label": "09 Aug", "count": 0, "score": null, "tone": "neutral", "x": 263.1, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-10", "label": "10 Aug", "count": 4, "score": 33, "tone": "negative", "x": 294.7, "y": 165.9, "volume_height": 29.7, "volume_y": 236.3}, {"date": "2026-08-11", "label": "11 Aug", "count": 1, "score": 50, "tone": "neutral", "x": 326.3, "y": 135.0, "volume_height": 7.4, "volume_y": 258.6}, {"date": "2026-08-12", "label": "12 Aug", "count": 2, "score": 50, "tone": "neutral", "x": 357.9, "y": 135.0, "volume_height": 14.9, "volume_y": 251.1}, {"date": "2026-08-13", "label": "13 Aug", "count": 0, "score": null, "tone": "neutral", "x": 389.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-14", "label": "14 Aug", "count": 2, "score": 47, "tone": "neutral", "x": 421.0, "y": 140.5, "volume_height": 14.9, "volume_y": 251.1}, {"date": "2026-08-15", "label": "15 Aug", "count": 0, "score": null, "tone": "neutral", "x": 452.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-16", "label": "16 Aug", "count": 0, "score": null, "tone": "neutral", "x": 484.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-17", "label": "17 Aug", "count": 1, "score": 59, "tone": "positive", "x": 515.8, "y": 118.6, "volume_height": 7.4, "volume_y": 258.6}, {"date": "2026-08-18", "label": "18 Aug", "count": 0, "score": null, "tone": "neutral", "x": 547.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-19", "label": "19 Aug", "count": 0, "score": null, "tone": "neutral", "x": 579.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-20", "label": "20 Aug", "count": 0, "score": null, "tone": "neutral", "x": 610.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-21", "label": "21 Aug", "count": 0, "score": null, "tone": "neutral", "x": 642.1, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-22", "label": "22 Aug", "count": 0, "score": null, "tone": "neutral", "x": 673.7, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-23", "label": "23 Aug", "count": 0, "score": null, "tone": "neutral", "x": 705.3, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-24", "label": "24 Aug", "count": 1, "score": 75, "tone": "positive", "x": 736.9, "y": 89.5, "volume_height": 7.4, "volume_y": 258.6}, {"date": "2026-08-25", "label": "25 Aug", "count": 0, "score": null, "tone": "neutral", "x": 768.5, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-26", "label": "26 Aug", "count": 1, "score": 50, "tone": "neutral", "x": 800.1, "y": 135.0, "volume_height": 7.4, "volume_y": 258.6}, {"date": "2026-08-27", "label": "27 Aug", "count": 0, "score": null, "tone": "neutral", "x": 831.7, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-28", "label": "28 Aug", "count": 0, "score": null, "tone": "neutral", "x": 863.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-29", "label": "29 Aug", "count": 0, "score": null, "tone": "neutral", "x": 894.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-30", "label": "30 Aug", "count": 0, "score": null, "tone": "neutral", "x": 926.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-31", "label": "31 Aug", "count": 0, "score": null, "tone": "neutral", "x": 958.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}], "timeline_points": "42.0,135.0 73.6,145.9 105.2,180.5 136.8,164.1 168.3,135.0 199.9,158.7 231.5,147.7 294.7,165.9 326.3,135.0 357.9,135.0 421.0,140.5 515.8,118.6 736.9,89.5 800.1,135.0", "timeline_has_signal": true, "timeline_start": "02 Aug", "timeline_mid": "17 Aug", "timeline_end": "31 Aug", "momentum": {"label": "Cooling", "tone": "neutral", "recent_score": null, "prior_score": 50, "delta": null, "recent_count": 0, "prior_count": 1, "volume_delta": -1, "reliable": false, "reliability_note": "Thin comparison; direction is not yet confirmed"}, "early_change": {"label": "No new story in 24 hours", "tone": "neutral", "latest_score": null, "baseline_score": 50, "delta": null, "latest_count": 0, "baseline_count": 1, "confirmed": false, "note": "A comparison needs current and earlier-week company news"}, "freshness_buckets": [{"label": "Last 24 hours", "count": 0, "share": 0}, {"label": "1 to 3 days", "count": 0, "share": 0}, {"label": "4 to 7 days", "count": 1, "share": 3}, {"label": "8 to 14 days", "count": 2, "share": 7}, {"label": "15 to 21 days", "count": 5, "share": 17}, {"label": "22 to 30 days", "count": 21, "share": 72}], "source_profile": [{"label": "The National Law Review", "count": 4, "share": 14, "score": 24, "tone": "negative"}, {"label": "TradingView", "count": 4, "share": 14, "score": 41, "tone": "negative"}, {"label": "vinanet.vn", "count": 2, "share": 7, "score": 71, "tone": "positive"}, {"label": "simplywall.st", "count": 2, "share": 7, "score": 50, "tone": "neutral"}, {"label": "Moomoo", "count": 2, "share": 7, "score": 50, "tone": "neutral"}, {"label": "MarketBeat", "count": 2, "share": 7, "score": 50, "tone": "neutral"}, {"label": "scanx.trade", "count": 1, "share": 3, "score": 75, "tone": "positive"}], "event_profile": [{"label": "Earnings", "count": 18, "share": 62, "score": 62, "tone": "positive"}, {"label": "Regulatory and legal", "count": 4, "share": 14, "score": 24, "tone": "negative"}, {"label": "Market update", "count": 3, "share": 10, "score": 50, "tone": "neutral"}, {"label": "Analyst action", "count": 2, "share": 7, "score": 58, "tone": "positive"}, {"label": "Balance sheet", "count": 1, "share": 3, "score": 50, "tone": "neutral"}, {"label": "Deals and strategy", "count": 1, "share": 3, "score": 50, "tone": "neutral"}], "topics": [{"label": "Life Sciences", "count": 17, "share": 59}, {"label": "Earnings", "count": 10, "share": 34}, {"label": "Finance", "count": 8, "share": 28}, {"label": "Financial Markets", "count": 5, "share": 17}, {"label": "EARNINGS", "count": 1, "share": 3}, {"label": "Clinical Trials", "count": 1, "share": 3}, {"label": "CLINICAL-TRIALS", "count": 1, "share": 3}, {"label": "Biotech", "count": 1, "share": 3}, {"label": "BIOTECH", "count": 1, "share": 3}], "supporting": [{"label": "Direct evidence", "text": "29 current stories are mapped specifically to ATYR."}, {"label": "Source breadth", "text": "The score uses 10 publishers rather than depending on one outlet."}], "tempering": [{"label": "Too little evidence", "text": "The stories agree, but freshness-weighted evidence is only 0.287."}, {"label": "Confidence", "text": "Confidence is 23/100, below the threshold for a firm score."}], "supporting_heading": "What supports the score", "tempering_heading": "What limits the score", "latest_observation": {"url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxQS2Q4TktPQWk1TTlvOU0zWklOVXF3VlV0WXRmWHdFSWdhQ25XSjBwcTRpZngyaS1pMUdnbWFUU0VXNm9JRkdMN2VyZ3dHY0tldzhCbDFLRkpucjh3cXdjREtVRE1fU1pyMjVBVWtROEdFN3k2aWNIYlBDWDcxM3JOd2MtcWM0TWJrdlpXQTJYM21pQV9XMjVpSm95NFVxUnNxaTFwWkhUYlNpZDNTbGhwUndWT1ZYWURyR0dpY3ZCMXlDSlJpZkdqUzFwSlowNm5NdUlPQk5OdTFyeW95SFHSAeMBQVVfeXFMUGgzVkpBMXp6MGhYUmF3ZHIwMHJDQ2lNTWJEZDIyWnRXQXdGYU9icU9KLUVhMUhUU1EzQ1o1MVFtVThqdTBPRzhoV0stV2VWakdDMHdnRHYyNXlFWmVyeGlWNUJ0eUdjemFXMXlIU1Y2bzFMdngwWldWZ1BRTGVsSnFOeFJSWTk2NEo4UjUxZjdwR2VVaGJpa3ZhWW0ycG5tTVN4d3Y1Mmw0RG9sSzh6YUtUS2ZReGFHU3RyVEZ0RDdTeml2M3o1aWRraHVYcGpIbm8zWDdZaVdxMjhhak03eU4wZ1E?oc=5", "tier": "direct", "title": "aTyr Pharma And 2 Other Penny Stocks With Promising Potential", "topics": [], "summary": "", "age_days": 4.6, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-08-26T17:24:07+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 20.4, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.01092, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "26 Aug 2026 17:24", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, "article_count": 29, "updated_at": "2026-08-31T07:24:45.447143+00:00"}, "price_sentiment_path": {"available": true, "price_points": [{"x": 42.0, "y": 91.7, "label": "06 Mar 2026", "close": 0.824, "index": 100.0}, {"x": 78.4, "y": 84.1, "label": "13 Mar 2026", "close": 0.85, "index": 103.2}, {"x": 114.9, "y": 96.3, "label": "20 Mar 2026", "close": 0.8083, "index": 98.1}, {"x": 151.3, "y": 112.8, "label": "27 Mar 2026", "close": 0.752, "index": 91.3}, {"x": 187.7, "y": 85.0, "label": "03 Apr 2026", "close": 0.8469, "index": 102.8}, {"x": 224.2, "y": 89.2, "label": "10 Apr 2026", "close": 0.8324, "index": 101.0}, {"x": 260.6, "y": 83.1, "label": "17 Apr 2026", "close": 0.8534, "index": 103.6}, {"x": 297.0, "y": 103.1, "label": "24 Apr 2026", "close": 0.7851, "index": 95.3}, {"x": 333.5, "y": 88.9, "label": "01 May 2026", "close": 0.8335, "index": 101.2}, {"x": 369.9, "y": 55.8, "label": "08 May 2026", "close": 0.9463, "index": 114.8}, {"x": 406.3, "y": 185.5, "label": "15 May 2026", "close": 0.504, "index": 61.2}, {"x": 442.8, "y": 189.6, "label": "22 May 2026", "close": 0.49, "index": 59.5}, {"x": 479.2, "y": 174.2, "label": "29 May 2026", "close": 0.5425, "index": 65.8}, {"x": 515.6, "y": 195.5, "label": "05 Jun 2026", "close": 0.47, "index": 57.0}, {"x": 552.0, "y": 204.2, "label": "12 Jun 2026", "close": 0.4404, "index": 53.4}, {"x": 588.5, "y": 201.2, "label": "19 Jun 2026", "close": 0.4505, "index": 54.7}, {"x": 624.9, "y": 178.6, "label": "26 Jun 2026", "close": 0.5275, "index": 64.0}, {"x": 661.3, "y": 159.6, "label": "03 Jul 2026", "close": 0.5925, "index": 71.9}, {"x": 697.8, "y": 173.7, "label": "10 Jul 2026", "close": 0.5444, "index": 66.1}, {"x": 734.2, "y": 183.8, "label": "17 Jul 2026", "close": 0.5098, "index": 61.9}, {"x": 770.6, "y": 194.5, "label": "24 Jul 2026", "close": 0.4733, "index": 57.4}, {"x": 807.1, "y": 190.9, "label": "31 Jul 2026", "close": 0.4857, "index": 58.9}, {"x": 843.5, "y": 183.4, "label": "07 Aug 2026", "close": 0.5114, "index": 62.1}, {"x": 879.9, "y": 169.4, "label": "14 Aug 2026", "close": 0.559, "index": 67.8}, {"x": 916.4, "y": 186.3, "label": "21 Aug 2026", "close": 0.5015, "index": 60.9}, {"x": 952.8, "y": 175.0, "label": "28 Aug 2026", "close": 0.54, "index": 65.5}], "sentiment_points": [{"at": "2026-03-06T23:59:59.999Z", "date": "2026-03-06", "tone": "neutral", "close": 0.824, "label": "06 Mar 2026", "score": 50, "stories": 1, "raw_score": 43, "confidence": 27, "price_change": null, "x": 47.2, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-03-13T23:59:59.999Z", "date": "2026-03-13", "tone": "neutral", "close": 0.85, "label": "13 Mar 2026", "score": 50, "stories": 1, "raw_score": 43, "confidence": 19, "price_change": 3.2, "x": 83.6, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-03-20T23:59:59.999Z", "date": "2026-03-20", "tone": "neutral", "close": 0.8083, "label": "20 Mar 2026", "score": 50, "stories": 1, "raw_score": 43, "confidence": 16, "price_change": -4.9, "x": 120.1, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-03-27T23:59:59.999Z", "date": "2026-03-27", "tone": "neutral", "close": 0.752, "label": "27 Mar 2026", "score": 50, "stories": 1, "raw_score": 43, "confidence": 14, "price_change": -7.0, "x": 156.5, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-04-03T23:59:59.999Z", "date": "2026-04-03", "tone": "neutral", "close": 0.8469, "label": "03 Apr 2026", "score": 50, "stories": 1, "raw_score": 43, "confidence": 14, "price_change": 12.6, "x": 192.9, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-04-17T23:59:59.999Z", "date": "2026-04-17", "tone": "neutral", "close": 0.8534, "label": "17 Apr 2026", "score": 50, "stories": 1, "raw_score": 50, "confidence": 0, "price_change": 2.5, "x": 265.8, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-04-24T23:59:59.999Z", "date": "2026-04-24", "tone": "neutral", "close": 0.7851, "label": "24 Apr 2026", "score": 50, "stories": 1, "raw_score": 50, "confidence": 0, "price_change": -8.0, "x": 302.2, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-05-01T23:59:59.999Z", "date": "2026-05-01", "tone": "neutral", "close": 0.8335, "label": "01 May 2026", "score": 50, "stories": 1, "raw_score": 50, "confidence": 0, "price_change": 6.2, "x": 338.7, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-05-08T23:59:59.999Z", "date": "2026-05-08", "tone": "neutral", "close": 0.9463, "label": "08 May 2026", "score": 50, "stories": 1, "raw_score": 50, "confidence": 0, "price_change": 13.5, "x": 375.1, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-05-15T23:59:59.999Z", "date": "2026-05-15", "tone": "neutral", "close": 0.504, "label": "15 May 2026", "score": 50, "stories": 3, "raw_score": 50, "confidence": 0, "price_change": -46.7, "x": 411.5, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-05-22T23:59:59.999Z", "date": "2026-05-22", "tone": "neutral", "close": 0.49, "label": "22 May 2026", "score": 50, "stories": 2, "raw_score": 50, "confidence": 0, "price_change": -2.8, "x": 448.0, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-05-29T23:59:59.999Z", "date": "2026-05-29", "tone": "neutral", "close": 0.5425, "label": "29 May 2026", "score": 50, "stories": 2, "raw_score": 50, "confidence": 0, "price_change": 10.7, "x": 484.4, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-06-05T23:59:59.999Z", "date": "2026-06-05", "tone": "neutral", "close": 0.47, "label": "05 Jun 2026", "score": 50, "stories": 2, "raw_score": 50, "confidence": 0, "price_change": -13.4, "x": 520.8, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-06-12T23:59:59.999Z", "date": "2026-06-12", "tone": "neutral", "close": 0.4404, "label": "12 Jun 2026", "score": 50, "stories": 2, "raw_score": 50, "confidence": 0, "price_change": -6.3, "x": 557.2, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-06-26T23:59:59.999Z", "date": "2026-06-26", "tone": "neutral", "close": 0.5275, "label": "26 Jun 2026", "score": 50, "stories": 1, "raw_score": 50, "confidence": 0, "price_change": 17.1, "x": 630.1, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-07-03T23:59:59.999Z", "date": "2026-07-03", "tone": "neutral", "close": 0.5925, "label": "03 Jul 2026", "score": 50, "stories": 2, "raw_score": 50, "confidence": 0, "price_change": 12.3, "x": 666.5, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-07-10T23:59:59.999Z", "date": "2026-07-10", "tone": "neutral", "close": 0.5444, "label": "10 Jul 2026", "score": 50, "stories": 5, "raw_score": 50, "confidence": 0, "price_change": -8.1, "x": 703.0, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-17T23:59:59.999Z", "date": "2026-07-17", "tone": "neutral", "close": 0.5098, "label": "17 Jul 2026", "score": 50, "stories": 8, "raw_score": 50, "confidence": 0, "price_change": -6.4, "x": 739.4, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-07-24T23:59:59.999Z", "date": "2026-07-24", "tone": "neutral", "close": 0.4733, "label": "24 Jul 2026", "score": 57, "stories": 12, "raw_score": 75, "confidence": 34, "price_change": -7.2, "x": 775.8, "y": 117.1, "show_label": false, "label_y": 107.1}, {"at": "2026-07-31T23:59:59.999Z", "date": "2026-07-31", "tone": "neutral", "close": 0.4857, "label": "31 Jul 2026", "score": 57, "stories": 22, "raw_score": 73, "confidence": 30, "price_change": 2.6, "x": 812.3, "y": 117.1, "show_label": false, "label_y": 107.1}, {"at": "2026-08-07T23:59:59.999Z", "date": "2026-08-07", "tone": "neutral", "close": 0.5114, "label": "07 Aug 2026", "score": 45, "stories": 36, "raw_score": 43, "confidence": 47, "price_change": 5.3, "x": 848.7, "y": 139.2, "show_label": true, "label_y": 129.2}, {"at": "2026-08-14T23:59:59.999Z", "date": "2026-08-14", "tone": "neutral", "close": 0.559, "label": "14 Aug 2026", "score": 44, "stories": 46, "raw_score": 38, "confidence": 37, "price_change": 9.3, "x": 885.1, "y": 141.0, "show_label": false, "label_y": 131.0}, {"at": "2026-08-21T23:59:59.999Z", "date": "2026-08-21", "tone": "neutral", "close": 0.5015, "label": "21 Aug 2026", "score": 46, "stories": 43, "raw_score": 37, "confidence": 27, "price_change": -10.3, "x": 921.6, "y": 137.4, "show_label": false, "label_y": 127.4}, {"at": "2026-08-28T23:59:59.999Z", "date": "2026-08-28", "tone": "neutral", "close": 0.54, "label": "28 Aug 2026", "score": 49, "stories": 32, "raw_score": 47, "confidence": 24, "price_change": 7.7, "x": 958.0, "y": 131.8, "show_label": true, "label_y": 121.80000000000001}], "price_path": "42.0,91.7 78.4,84.1 114.9,96.3 151.3,112.8 187.7,85.0 224.2,89.2 260.6,83.1 297.0,103.1 333.5,88.9 369.9,55.8 406.3,185.5 442.8,189.6 479.2,174.2 515.6,195.5 552.0,204.2 588.5,201.2 624.9,178.6 661.3,159.6 697.8,173.7 734.2,183.8 770.6,194.5 807.1,190.9 843.5,183.4 879.9,169.4 916.4,186.3 952.8,175.0", "sentiment_path": "47.2,130.0 83.6,130.0 120.1,130.0 156.5,130.0 192.9,130.0 265.8,130.0 302.2,130.0 338.7,130.0 375.1,130.0 411.5,130.0 448.0,130.0 484.4,130.0 520.8,130.0 557.2,130.0 630.1,130.0 666.5,130.0 703.0,130.0 739.4,130.0 775.8,117.1 812.3,117.1 848.7,139.2 885.1,141.0 921.6,137.4 958.0,131.8", "score_version": "evidence-v10", "price_change": -34.5, "sentiment_change": -1, "recent_pairs": [{"at": "2026-08-28T23:59:59.999Z", "date": "2026-08-28", "tone": "neutral", "close": 0.54, "label": "28 Aug 2026", "score": 49, "stories": 32, "raw_score": 47, "confidence": 24, "price_change": 7.7, "x": 958.0, "y": 131.8, "show_label": true, "label_y": 121.80000000000001}, {"at": "2026-08-21T23:59:59.999Z", "date": "2026-08-21", "tone": "neutral", "close": 0.5015, "label": "21 Aug 2026", "score": 46, "stories": 43, "raw_score": 37, "confidence": 27, "price_change": -10.3, "x": 921.6, "y": 137.4, "show_label": false, "label_y": 127.4}, {"at": "2026-08-14T23:59:59.999Z", "date": "2026-08-14", "tone": "neutral", "close": 0.559, "label": "14 Aug 2026", "score": 44, "stories": 46, "raw_score": 38, "confidence": 37, "price_change": 9.3, "x": 885.1, "y": 141.0, "show_label": false, "label_y": 131.0}, {"at": "2026-08-07T23:59:59.999Z", "date": "2026-08-07", "tone": "neutral", "close": 0.5114, "label": "07 Aug 2026", "score": 45, "stories": 36, "raw_score": 43, "confidence": 47, "price_change": 5.3, "x": 848.7, "y": 139.2, "show_label": true, "label_y": 129.2}, {"at": "2026-07-31T23:59:59.999Z", "date": "2026-07-31", "tone": "neutral", "close": 0.4857, "label": "31 Jul 2026", "score": 57, "stories": 22, "raw_score": 73, "confidence": 30, "price_change": 2.6, "x": 812.3, "y": 117.1, "show_label": false, "label_y": 107.1}, {"at": "2026-07-24T23:59:59.999Z", "date": "2026-07-24", "tone": "neutral", "close": 0.4733, "label": "24 Jul 2026", "score": 57, "stories": 12, "raw_score": 75, "confidence": 34, "price_change": -7.2, "x": 775.8, "y": 117.1, "show_label": false, "label_y": 107.1}, {"at": "2026-07-17T23:59:59.999Z", "date": "2026-07-17", "tone": "neutral", "close": 0.5098, "label": "17 Jul 2026", "score": 50, "stories": 8, "raw_score": 50, "confidence": 0, "price_change": -6.4, "x": 739.4, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-07-10T23:59:59.999Z", "date": "2026-07-10", "tone": "neutral", "close": 0.5444, "label": "10 Jul 2026", "score": 50, "stories": 5, "raw_score": 50, "confidence": 0, "price_change": -8.1, "x": 703.0, "y": 130.0, "show_label": true, "label_y": 120.0}], "reconstructed": true, "latest_close": 0.54, "price_observations": 26, "sentiment_observations": 24, "sentiment_start_label": "06 Mar 2026", "sentiment_end_label": "28 Aug 2026", "sentiment_history_limited": false, "price_axis_high": 122.2, "price_axis_mid": 84.1, "price_axis_low": 46.1, "start_label": "06 Mar", "mid_label": "02 Jun", "end_label": "28 Aug", "live_score_version": "evidence-v10", "comparable_to_live": true}, "sentiment_history": [{"tone": "neutral", "delta": 0, "label": "17 Apr 23:59", "score": 50, "height": 4, "articles": 1, "confidence": 0, "short_label": "17 Apr", "collected_at": "2026-04-17T23:59:59.999999+00:00", "score_change": null, "reconstructed": true, "score_version": "evidence-v10", "article_change": null, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": null, "score_change_display": "Start"}, {"tone": "neutral", "delta": 0, "label": "15 May 23:59", "score": 50, "height": 4, "articles": 3, "confidence": 0, "short_label": "15 May", "collected_at": "2026-05-15T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": 0, "score_change_display": "+0"}, {"tone": "neutral", "delta": 0, "label": "25 Jun 23:59", "score": 50, "height": 4, "articles": 1, "confidence": 0, "short_label": "25 Jun", "collected_at": "2026-06-25T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": -2, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": 0, "score_change_display": "+0"}, {"tone": "neutral", "delta": 0, "label": "27 Jun 23:59", "score": 50, "height": 4, "articles": 2, "confidence": 0, "short_label": "27 Jun", "collected_at": "2026-06-27T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": 0, "score_change_display": "+0"}, {"tone": "neutral", "delta": 0, "label": "04 Jul 23:59", "score": 50, "height": 4, "articles": 3, "confidence": 0, "short_label": "04 Jul", "collected_at": "2026-07-04T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": 0, "score_change_display": "+0"}, {"tone": "neutral", "delta": 0, "label": "06 Jul 23:59", "score": 50, "height": 4, "articles": 4, "confidence": 0, "short_label": "06 Jul", "collected_at": "2026-07-06T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": 0, "score_change_display": "+0"}, {"tone": "neutral", "delta": 0, "label": "10 Jul 23:59", "score": 50, "height": 4, "articles": 5, "confidence": 0, "short_label": "10 Jul", "collected_at": "2026-07-10T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": 0, "score_change_display": "+0"}, {"tone": "neutral", "delta": 0, "label": "16 Jul 23:59", "score": 50, "height": 4, "articles": 8, "confidence": 0, "short_label": "16 Jul", "collected_at": "2026-07-16T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 3, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": 0, "score_change_display": "+0"}, {"tone": "neutral", "delta": 0, "label": "21 Jul 23:59", "score": 50, "height": 4, "articles": 9, "confidence": 0, "short_label": "21 Jul", "collected_at": "2026-07-21T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": 0, "score_change_display": "+0"}, {"tone": "neutral", "delta": 6, "label": "23 Jul 23:59", "score": 56, "height": 12, "articles": 10, "confidence": 31, "short_label": "23 Jul", "collected_at": "2026-07-23T23:59:59.999999+00:00", "score_change": 6, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 31, "score_change_display": "+6"}, {"tone": "neutral", "delta": 7, "label": "24 Jul 23:59", "score": 57, "height": 14, "articles": 12, "confidence": 34, "short_label": "24 Jul", "collected_at": "2026-07-24T23:59:59.999999+00:00", "score_change": 1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 3, "score_change_display": "+1"}, {"tone": "neutral", "delta": 5, "label": "25 Jul 23:59", "score": 55, "height": 10, "articles": 14, "confidence": 35, "short_label": "25 Jul", "collected_at": "2026-07-25T23:59:59.999999+00:00", "score_change": -2, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 1, "score_change_display": "-2"}, {"tone": "neutral", "delta": 4, "label": "27 Jul 23:59", "score": 54, "height": 8, "articles": 16, "confidence": 29, "short_label": "27 Jul", "collected_at": "2026-07-27T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -6, "score_change_display": "-1"}, {"tone": "positive", "delta": 8, "label": "29 Jul 23:59", "score": 58, "height": 16, "articles": 20, "confidence": 33, "short_label": "29 Jul", "collected_at": "2026-07-29T23:59:59.999999+00:00", "score_change": 4, "reconstructed": true, "score_version": "evidence-v10", "article_change": 4, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 4, "score_change_display": "+4"}, {"tone": "positive", "delta": 8, "label": "30 Jul 23:59", "score": 58, "height": 16, "articles": 21, "confidence": 31, "short_label": "30 Jul", "collected_at": "2026-07-30T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "+0"}, {"tone": "neutral", "delta": 7, "label": "31 Jul 23:59", "score": 57, "height": 14, "articles": 22, "confidence": 30, "short_label": "31 Jul", "collected_at": "2026-07-31T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -1, "score_change_display": "-1"}, {"tone": "neutral", "delta": 6, "label": "01 Aug 23:59", "score": 56, "height": 12, "articles": 23, "confidence": 27, "short_label": "01 Aug", "collected_at": "2026-08-01T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -3, "score_change_display": "-1"}, {"tone": "neutral", "delta": 6, "label": "02 Aug 23:59", "score": 56, "height": 12, "articles": 24, "confidence": 25, "short_label": "02 Aug", "collected_at": "2026-08-02T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "+0"}, {"tone": "neutral", "delta": 3, "label": "03 Aug 23:59", "score": 53, "height": 6, "articles": 26, "confidence": 31, "short_label": "03 Aug", "collected_at": "2026-08-03T23:59:59.999999+00:00", "score_change": -3, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 6, "score_change_display": "-3"}, {"tone": "neutral", "delta": -2, "label": "04 Aug 23:59", "score": 48, "height": 4, "articles": 28, "confidence": 37, "short_label": "04 Aug", "collected_at": "2026-08-04T23:59:59.999999+00:00", "score_change": -5, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 6, "score_change_display": "-5"}, {"tone": "neutral", "delta": -3, "label": "05 Aug 23:59", "score": 47, "height": 6, "articles": 28, "confidence": 38, "short_label": "05 Aug", "collected_at": "2026-08-05T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 0, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": 1, "score_change_display": "-1"}, {"tone": "neutral", "delta": -3, "label": "06 Aug 23:59", "score": 47, "height": 6, "articles": 29, "confidence": 36, "short_label": "06 Aug", "collected_at": "2026-08-06T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "+0"}, {"tone": "neutral", "delta": -5, "label": "07 Aug 23:59", "score": 45, "height": 10, "articles": 36, "confidence": 47, "short_label": "07 Aug", "collected_at": "2026-08-07T23:59:59.999999+00:00", "score_change": -2, "reconstructed": true, "score_version": "evidence-v10", "article_change": 7, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": 11, "score_change_display": "-2"}, {"tone": "neutral", "delta": -5, "label": "08 Aug 23:59", "score": 45, "height": 10, "articles": 38, "confidence": 45, "short_label": "08 Aug", "collected_at": "2026-08-08T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": -2, "score_change_display": "+0"}, {"tone": "neutral", "delta": -7, "label": "10 Aug 23:59", "score": 43, "height": 14, "articles": 41, "confidence": 45, "short_label": "10 Aug", "collected_at": "2026-08-10T23:59:59.999999+00:00", "score_change": -2, "reconstructed": true, "score_version": "evidence-v10", "article_change": 3, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": 0, "score_change_display": "-2"}, {"tone": "neutral", "delta": -7, "label": "11 Aug 23:59", "score": 43, "height": 14, "articles": 42, "confidence": 42, "short_label": "11 Aug", "collected_at": "2026-08-11T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": -3, "score_change_display": "+0"}, {"tone": "neutral", "delta": -7, "label": "12 Aug 23:59", "score": 43, "height": 14, "articles": 44, "confidence": 40, "short_label": "12 Aug", "collected_at": "2026-08-12T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": -2, "score_change_display": "+0"}, {"tone": "neutral", "delta": -6, "label": "14 Aug 23:59", "score": 44, "height": 12, "articles": 46, "confidence": 37, "short_label": "14 Aug", "collected_at": "2026-08-14T23:59:59.999999+00:00", "score_change": 1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": -3, "score_change_display": "+1"}, {"tone": "neutral", "delta": -5, "label": "17 Aug 23:59", "score": 45, "height": 10, "articles": 44, "confidence": 33, "short_label": "17 Aug", "collected_at": "2026-08-17T23:59:59.999999+00:00", "score_change": 1, "reconstructed": true, "score_version": "evidence-v10", "article_change": -2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -4, "score_change_display": "+1"}, {"tone": "neutral", "delta": 0, "label": "24 Aug 23:59", "score": 50, "height": 4, "articles": 38, "confidence": 30, "short_label": "24 Aug", "collected_at": "2026-08-24T23:59:59.999999+00:00", "score_change": 5, "reconstructed": true, "score_version": "evidence-v10", "article_change": -6, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -3, "score_change_display": "+5"}, {"tone": "neutral", "delta": 0, "label": "26 Aug 23:59", "score": 50, "height": 4, "articles": 36, "confidence": 26, "short_label": "26 Aug", "collected_at": "2026-08-26T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": -2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -4, "score_change_display": "+0"}, {"tone": "neutral", "delta": -1, "label": "31 Aug 07:24", "score": 49, "height": 4, "articles": 29, "confidence": 22, "short_label": "31 Aug", "collected_at": "2026-08-31T07:24:45.194023+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": -7, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -4, "score_change_display": "-1"}], "sentiment_history_insight": {"available": true, "series_version": "evidence-v10", "live_version": "evidence-v10", "comparable_to_live": true, "reconstructed": true, "observations": 32, "span_label": "135 days", "first_score": 50, "latest_score": 49, "net_change": -1, "net_change_display": "-1", "direction": "Broadly stable", "high_score": 58, "low_score": 43, "latest_confidence": 22, "confidence_change": 22, "latest_articles": 29, "article_change": 28, "latest_label": "31 Aug 07:24", "latest_evidence_label": "Provisional", "chart_rows": [{"tone": "neutral", "delta": 0, "label": "17 Apr 23:59", "score": 50, "height": 4, "articles": 1, "confidence": 0, "short_label": "17 Apr", "collected_at": "2026-04-17T23:59:59.999999+00:00", "score_change": null, "reconstructed": true, "score_version": "evidence-v10", "article_change": null, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": null, "score_change_display": "Start", "x": 42.0, "y": 135.0}, {"tone": "neutral", "delta": 0, "label": "15 May 23:59", "score": 50, "height": 4, "articles": 3, "confidence": 0, "short_label": "15 May", "collected_at": "2026-05-15T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": 0, "score_change_display": "+0", "x": 71.5, "y": 135.0}, {"tone": "neutral", "delta": 0, "label": "25 Jun 23:59", "score": 50, "height": 4, "articles": 1, "confidence": 0, "short_label": "25 Jun", "collected_at": "2026-06-25T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": -2, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": 0, "score_change_display": "+0", "x": 101.1, "y": 135.0}, {"tone": "neutral", "delta": 0, "label": "27 Jun 23:59", "score": 50, "height": 4, "articles": 2, "confidence": 0, "short_label": "27 Jun", "collected_at": "2026-06-27T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": 0, "score_change_display": "+0", "x": 130.6, "y": 135.0}, {"tone": "neutral", "delta": 0, "label": "04 Jul 23:59", "score": 50, "height": 4, "articles": 3, "confidence": 0, "short_label": "04 Jul", "collected_at": "2026-07-04T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": 0, "score_change_display": "+0", "x": 160.2, "y": 135.0}, {"tone": "neutral", "delta": 0, "label": "06 Jul 23:59", "score": 50, "height": 4, "articles": 4, "confidence": 0, "short_label": "06 Jul", "collected_at": "2026-07-06T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": 0, "score_change_display": "+0", "x": 189.7, "y": 135.0}, {"tone": "neutral", "delta": 0, "label": "10 Jul 23:59", "score": 50, "height": 4, "articles": 5, "confidence": 0, "short_label": "10 Jul", "collected_at": "2026-07-10T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": 0, "score_change_display": "+0", "x": 219.3, "y": 135.0}, {"tone": "neutral", "delta": 0, "label": "16 Jul 23:59", "score": 50, "height": 4, "articles": 8, "confidence": 0, "short_label": "16 Jul", "collected_at": "2026-07-16T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 3, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": 0, "score_change_display": "+0", "x": 248.8, "y": 135.0}, {"tone": "neutral", "delta": 0, "label": "21 Jul 23:59", "score": 50, "height": 4, "articles": 9, "confidence": 0, "short_label": "21 Jul", "collected_at": "2026-07-21T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": 0, "score_change_display": "+0", "x": 278.4, "y": 135.0}, {"tone": "neutral", "delta": 6, "label": "23 Jul 23:59", "score": 56, "height": 12, "articles": 10, "confidence": 31, "short_label": "23 Jul", "collected_at": "2026-07-23T23:59:59.999999+00:00", "score_change": 6, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 31, "score_change_display": "+6", "x": 307.9, "y": 124.1}, {"tone": "neutral", "delta": 7, "label": "24 Jul 23:59", "score": 57, "height": 14, "articles": 12, "confidence": 34, "short_label": "24 Jul", "collected_at": "2026-07-24T23:59:59.999999+00:00", "score_change": 1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 3, "score_change_display": "+1", "x": 337.5, "y": 122.3}, {"tone": "neutral", "delta": 5, "label": "25 Jul 23:59", "score": 55, "height": 10, "articles": 14, "confidence": 35, "short_label": "25 Jul", "collected_at": "2026-07-25T23:59:59.999999+00:00", "score_change": -2, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 1, "score_change_display": "-2", "x": 367.0, "y": 125.9}, {"tone": "neutral", "delta": 4, "label": "27 Jul 23:59", "score": 54, "height": 8, "articles": 16, "confidence": 29, "short_label": "27 Jul", "collected_at": "2026-07-27T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -6, "score_change_display": "-1", "x": 396.6, "y": 127.7}, {"tone": "positive", "delta": 8, "label": "29 Jul 23:59", "score": 58, "height": 16, "articles": 20, "confidence": 33, "short_label": "29 Jul", "collected_at": "2026-07-29T23:59:59.999999+00:00", "score_change": 4, "reconstructed": true, "score_version": "evidence-v10", "article_change": 4, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 4, "score_change_display": "+4", "x": 426.1, "y": 120.4}, {"tone": "positive", "delta": 8, "label": "30 Jul 23:59", "score": 58, "height": 16, "articles": 21, "confidence": 31, "short_label": "30 Jul", "collected_at": "2026-07-30T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "+0", "x": 455.7, "y": 120.4}, {"tone": "neutral", "delta": 7, "label": "31 Jul 23:59", "score": 57, "height": 14, "articles": 22, "confidence": 30, "short_label": "31 Jul", "collected_at": "2026-07-31T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -1, "score_change_display": "-1", "x": 485.2, "y": 122.3}, {"tone": "neutral", "delta": 6, "label": "01 Aug 23:59", "score": 56, "height": 12, "articles": 23, "confidence": 27, "short_label": "01 Aug", "collected_at": "2026-08-01T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -3, "score_change_display": "-1", "x": 514.8, "y": 124.1}, {"tone": "neutral", "delta": 6, "label": "02 Aug 23:59", "score": 56, "height": 12, "articles": 24, "confidence": 25, "short_label": "02 Aug", "collected_at": "2026-08-02T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "+0", "x": 544.3, "y": 124.1}, {"tone": "neutral", "delta": 3, "label": "03 Aug 23:59", "score": 53, "height": 6, "articles": 26, "confidence": 31, "short_label": "03 Aug", "collected_at": "2026-08-03T23:59:59.999999+00:00", "score_change": -3, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 6, "score_change_display": "-3", "x": 573.9, "y": 129.5}, {"tone": "neutral", "delta": -2, "label": "04 Aug 23:59", "score": 48, "height": 4, "articles": 28, "confidence": 37, "short_label": "04 Aug", "collected_at": "2026-08-04T23:59:59.999999+00:00", "score_change": -5, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 6, "score_change_display": "-5", "x": 603.4, "y": 138.6}, {"tone": "neutral", "delta": -3, "label": "05 Aug 23:59", "score": 47, "height": 6, "articles": 28, "confidence": 38, "short_label": "05 Aug", "collected_at": "2026-08-05T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 0, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": 1, "score_change_display": "-1", "x": 633.0, "y": 140.5}, {"tone": "neutral", "delta": -3, "label": "06 Aug 23:59", "score": 47, "height": 6, "articles": 29, "confidence": 36, "short_label": "06 Aug", "collected_at": "2026-08-06T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "+0", "x": 662.5, "y": 140.5}, {"tone": "neutral", "delta": -5, "label": "07 Aug 23:59", "score": 45, "height": 10, "articles": 36, "confidence": 47, "short_label": "07 Aug", "collected_at": "2026-08-07T23:59:59.999999+00:00", "score_change": -2, "reconstructed": true, "score_version": "evidence-v10", "article_change": 7, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": 11, "score_change_display": "-2", "x": 692.1, "y": 144.1}, {"tone": "neutral", "delta": -5, "label": "08 Aug 23:59", "score": 45, "height": 10, "articles": 38, "confidence": 45, "short_label": "08 Aug", "collected_at": "2026-08-08T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": -2, "score_change_display": "+0", "x": 721.6, "y": 144.1}, {"tone": "neutral", "delta": -7, "label": "10 Aug 23:59", "score": 43, "height": 14, "articles": 41, "confidence": 45, "short_label": "10 Aug", "collected_at": "2026-08-10T23:59:59.999999+00:00", "score_change": -2, "reconstructed": true, "score_version": "evidence-v10", "article_change": 3, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": 0, "score_change_display": "-2", "x": 751.2, "y": 147.7}, {"tone": "neutral", "delta": -7, "label": "11 Aug 23:59", "score": 43, "height": 14, "articles": 42, "confidence": 42, "short_label": "11 Aug", "collected_at": "2026-08-11T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": -3, "score_change_display": "+0", "x": 780.7, "y": 147.7}, {"tone": "neutral", "delta": -7, "label": "12 Aug 23:59", "score": 43, "height": 14, "articles": 44, "confidence": 40, "short_label": "12 Aug", "collected_at": "2026-08-12T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": -2, "score_change_display": "+0", "x": 810.3, "y": 147.7}, {"tone": "neutral", "delta": -6, "label": "14 Aug 23:59", "score": 44, "height": 12, "articles": 46, "confidence": 37, "short_label": "14 Aug", "collected_at": "2026-08-14T23:59:59.999999+00:00", "score_change": 1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": -3, "score_change_display": "+1", "x": 839.8, "y": 145.9}, {"tone": "neutral", "delta": -5, "label": "17 Aug 23:59", "score": 45, "height": 10, "articles": 44, "confidence": 33, "short_label": "17 Aug", "collected_at": "2026-08-17T23:59:59.999999+00:00", "score_change": 1, "reconstructed": true, "score_version": "evidence-v10", "article_change": -2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -4, "score_change_display": "+1", "x": 869.4, "y": 144.1}, {"tone": "neutral", "delta": 0, "label": "24 Aug 23:59", "score": 50, "height": 4, "articles": 38, "confidence": 30, "short_label": "24 Aug", "collected_at": "2026-08-24T23:59:59.999999+00:00", "score_change": 5, "reconstructed": true, "score_version": "evidence-v10", "article_change": -6, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -3, "score_change_display": "+5", "x": 898.9, "y": 135.0}, {"tone": "neutral", "delta": 0, "label": "26 Aug 23:59", "score": 50, "height": 4, "articles": 36, "confidence": 26, "short_label": "26 Aug", "collected_at": "2026-08-26T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": -2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -4, "score_change_display": "+0", "x": 928.5, "y": 135.0}, {"tone": "neutral", "delta": -1, "label": "31 Aug 07:24", "score": 49, "height": 4, "articles": 29, "confidence": 22, "short_label": "31 Aug", "collected_at": "2026-08-31T07:24:45.194023+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": -7, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -4, "score_change_display": "-1", "x": 958.0, "y": 136.8}], "chart_points": "42.0,135.0 71.5,135.0 101.1,135.0 130.6,135.0 160.2,135.0 189.7,135.0 219.3,135.0 248.8,135.0 278.4,135.0 307.9,124.1 337.5,122.3 367.0,125.9 396.6,127.7 426.1,120.4 455.7,120.4 485.2,122.3 514.8,124.1 544.3,124.1 573.9,129.5 603.4,138.6 633.0,140.5 662.5,140.5 692.1,144.1 721.6,144.1 751.2,147.7 780.7,147.7 810.3,147.7 839.8,145.9 869.4,144.1 898.9,135.0 928.5,135.0 958.0,136.8", "changes": [{"tone": "neutral", "delta": -1, "label": "31 Aug 07:24", "score": 49, "height": 4, "articles": 29, "confidence": 22, "short_label": "31 Aug", "collected_at": "2026-08-31T07:24:45.194023+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": -7, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -4, "score_change_display": "-1"}, {"tone": "neutral", "delta": 0, "label": "26 Aug 23:59", "score": 50, "height": 4, "articles": 36, "confidence": 26, "short_label": "26 Aug", "collected_at": "2026-08-26T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": -2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -4, "score_change_display": "+0"}, {"tone": "neutral", "delta": 0, "label": "24 Aug 23:59", "score": 50, "height": 4, "articles": 38, "confidence": 30, "short_label": "24 Aug", "collected_at": "2026-08-24T23:59:59.999999+00:00", "score_change": 5, "reconstructed": true, "score_version": "evidence-v10", "article_change": -6, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -3, "score_change_display": "+5"}, {"tone": "neutral", "delta": -5, "label": "17 Aug 23:59", "score": 45, "height": 10, "articles": 44, "confidence": 33, "short_label": "17 Aug", "collected_at": "2026-08-17T23:59:59.999999+00:00", "score_change": 1, "reconstructed": true, "score_version": "evidence-v10", "article_change": -2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -4, "score_change_display": "+1"}, {"tone": "neutral", "delta": -6, "label": "14 Aug 23:59", "score": 44, "height": 12, "articles": 46, "confidence": 37, "short_label": "14 Aug", "collected_at": "2026-08-14T23:59:59.999999+00:00", "score_change": 1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": -3, "score_change_display": "+1"}, {"tone": "neutral", "delta": -7, "label": "12 Aug 23:59", "score": 43, "height": 14, "articles": 44, "confidence": 40, "short_label": "12 Aug", "collected_at": "2026-08-12T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": -2, "score_change_display": "+0"}, {"tone": "neutral", "delta": -7, "label": "11 Aug 23:59", "score": 43, "height": 14, "articles": 42, "confidence": 42, "short_label": "11 Aug", "collected_at": "2026-08-11T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": -3, "score_change_display": "+0"}, {"tone": "neutral", "delta": -7, "label": "10 Aug 23:59", "score": 43, "height": 14, "articles": 41, "confidence": 45, "short_label": "10 Aug", "collected_at": "2026-08-10T23:59:59.999999+00:00", "score_change": -2, "reconstructed": true, "score_version": "evidence-v10", "article_change": 3, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": 0, "score_change_display": "-2"}]}, "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}